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ABSTRACT 
 
A hallmark of high grade glioma is highly aggressive, diffuse invasion into normal 
brain tissue, contributing to a 100% recurrence rate and resistance to current therapies. 
Recent efforts to determine molecular differences in high grade glioma and define tumor 
subtypes have revealed that the noncanonical NF-B transcription factor RelB is 
upregulated in the highly aggressive mesenchymal subtype, as well as in recurrent tumors. 
The studies presented here seek to better understand how noncanonical NF-B signaling 
drives glioma cell invasion in a three-dimensional (3D) environment. Stabilization of NF-
B-inducing kinase (NIK), a critical driver of noncanonical NF-B signaling, promoted 
glioma cell adhesion, spreading, and pseudopodia formation on collagen, which is 
expressed at low levels in normal brain tissue but highly upregulated within the stroma 
and surrounding tissue of glioma. As NIK expression appeared to regulate glioma cell 
behavior on collagen, we investigated whether NIK controls the expression of integrins 
known to bind collagen. We found NIK expression upregulated the integrin alpha 11 
subunit (ITGA11), while it did not significantly affect the expression of ITGA1, ITGA2, 
or ITGA10. Analysis of human tumor samples revealed that ITGA11 expression was 
increased in glioma tissue compared to normal brain tissue. Furthermore, when testing 
multiple glioma lines, ITGA11 expression positively correlated with invasiveness into 3D 
collagen matrices. Investigation of a key transmembrane metalloproteinase revealed that 
NIK expression enhanced the localization of active, phosphorylated membrane-type 1 
matrix metalloproteinase (MT1-MMP) to pseudopodial structures. In a heterologous 
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system, ITGA11 and MT1-MMP formed a complex, suggesting these transmembrane 
proteins could interact in glioma cells to facilitate coordinated recognition and degradation 
of collagen during invasion. Finally, silencing of ITGA11 in an invasive glioma line 
attenuated invasion into 3D collagen matrices. Collectively, these data reveal an ability of 
NIK to promote directed glioma cell invasion, pseudopodia formation, ITGA11 
expression, and activated MT1-MMP localization to pseudopodia. These data suggest 
ITGA11 could serve as a novel marker for more invasive glioma and a potential 
therapeutic target in glioma.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
HIGH GRADE GLIOMA  
Gliomas are the most common and lethal primary central nervous system (CNS) 
tumors in adults, and the leading cause of cancer death in children. They are classified by 
the World Health Organization into grades I-IV, based on mitotic index, cellular density, 
detection of necrosis, and glial cell types identified. High grade gliomas (grades III-IV) 
are the most common and malignant, representing about 60-75% of all gliomas (1, 2). 
Though the cell type of origin remains under debate, high grade gliomas are suggested to 
be derived through either the transformation of a neural stem cell or glial progenitor cell 
or through the dedifferentiation of a mature glial cell (3, 4). These tumors exhibit 
aggressive invasion into the surrounding healthy brain tissue, though they rarely 
metastasize outside the CNS. Infiltration of the normal brain makes complete surgical 
removal of the tumor a considerable challenge as this would significantly compromise 
neurological function and quality of life. The current treatment regime for high grade 
glioma consists of surgery to remove the bulk of the tumor mass, followed by concurrent 
radiotherapy and chemotherapy with the cytotoxic DNA alkylating agent, temozolomide 
(5, 6). Despite this aggressive treatment, high grade gliomas continue to be one of the 
deadliest cancers with a median survival time between 12 and 15 months (5, 7). Partial 
removal of the tumor allows the cells that invaded past the margins of resection to regrow 
the tumor mass, leading to a recurrence rate of 100%.  
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 Several monogenic Mendelian disorders are linked to an increased risk of 
developing a glioma as an adult, though these patients make up a small portion of the cases 
(8). Neurofibromatosis 1 and 2, Lynch syndrome and Li-Fraumeni syndrome are a few 
examples, although these disorders give genetic predisposition to cancers outside the brain 
as well (8). However, efforts to understand the molecular pathology of high grade glioma 
have revealed somatic genetic alterations in several signaling pathways (9, 10). Genomic 
and transcriptomic analysis of glioblastoma by The Cancer Genome Atlas Network found 
several pathways commonly mutated in glioblastoma, including p53 (TP53, MDM2, and 
MDM4), Rb (CDKN2A, CDKN2B, CDK4, and RB1), and the PI3K and MAPK pathways 
(EGFR, PDGFRA, PTEN, PI(3)K, and NF1) (9, 10).  
This gene expression data was used to divide glioblastoma tumors into four 
subtypes, Proneural, Neural, Classical, and Mesenchymal (11). The Proneural subtype was 
most frequent in patients under the age of 40, and was characterized by increased 
expression of PDGFRA and mutations of IDH1, and TP53. The Neural subtype displayed 
an expression pattern similar to neurons, and these tumors were suggested to be derived 
from a more differentiated cell. Amplification of EGFR was most frequently found in the 
Classical subtype. Necrosis was most common in the Mesenchymal subtype, as was an 
increase in expression of mesenchymal markers and genes in the NF-B pathway, 
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NONCANONICAL NF-B SIGNALING 
 NF-B signaling is divided into two main pathways, the canonical pathway with 
transcription factors p65 (RELA), p50 (NFKB1), and c-Rel (REL), and the noncanonical 
pathway with transcription factors RelB (RELB) and p52 (NFKB2). The noncanonical 
pathway regulates several biological processes, including B-cell maturation and survival, 
lymphoid organ development, and osteoclast differentiation. This pathway relies on the 
partial processing of the protein, p100 which acts as both an inhibitor to RelB nuclear 
translocation, and as a precursor of the transcription factor, p52. Noncanonical NF-B 
signaling is initiated by activation of specific TNFR superfamily members, including 
FN14 (12), B-cell activating factor belonging to TNF family receptor (BAFFR) (13), 
lymphotoxin -receptor (LTR) (14), receptor activator for nuclear factor B (RANK) 
(15), and TNFR2 (16). Receptor activation leads to stabilization and accumulation of the 
protein, NF-B-inducing kinase (NIK or MAP3K14). When cells are unstimulated, NIK 
interacts with TRAF3 at the N-terminus. After binding NIK, TRAF3 is recruited to the 
cIAP1/2 E3 ubiquitin ligase complex through binding to TRAF2. cIAP1/2 ubiquitinylates 
NIK at K48, leading to its proteasomal degradation. NIK can also be phosphorylated by 
IKK or TANK-binding kinase 1 (TBK1) leading to NIK proteolysis (17, 18). However, 
after stimulation of the specific TNF receptors, TRAF3 and TRAF2 are recruited to the 
activated receptor, leading degradation mediated by ubiquitinylation by cIAP1/2. NIK 
accumulation causes autophosphorylation, leading to downstream phosphorylation of 
IKK. Activated IKK then mediates the phosphorylation and partial processing of the 
C-terminus of p100 to p52 through ubiquitinylation by TrCP. p52-RelB heterodimers 
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can then translocate to the nucleus where they recognize and bind B sites on target genes 
(19, 20). 
While the role of canonical NF-B signaling in immune function and cancer 
development and progression has been thoroughly investigated (21), much less is known 
of how the noncanonical NF-B pathway contributes to the development of disease. 
Impaired noncanonical NF-B signaling is associated with compromised lymphoid 
organogenesis and B-cell maturation (22, 23). Mutations leading to increased activation 
of noncanonical NF-B signaling are associated with several cancers, including multiple 
myeloma, diffuse large B cell lymphoma, Hodgkin’s lymphoma, lung cancer, ovarian 
cancer, and prostate cancer (24-28).  
Our previous work has found more invasive glioblastoma cell lines display 
increased expression of RelB, and knockdown of RelB attenuates glioma cell invasion and 
tumor progression (29, 30). Further, increased expression of NIK promotes glioma tumor 
progression in orthotopic tumor xenografts (30). However, the mechanism through which 
noncanonical NF-B signaling pathway promotes glioma cell invasion is unknown. 
INTEGRINS 
Integrins are a large family of cell adhesion molecules which facilitate cell-cell 
and cell-matrix interactions. The integrin family is composed of 18 alpha subunits which 
can heterodimerize with 8 beta subunits to form 24 known integrin pairs (31, 32). The 
alpha and beta subunits are non-covalently linked transmembrane proteins that function 
to connect the actin cytoskeleton to the ECM. Integrins are critical for mediating cell 
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adhesion and migration, as well as for integrating signals from both inside and outside the 
cell. Integrin clustering after matrix adhesion leads to outside-in signaling, while 
conformational changes to a high-affinity state facilitate inside-out signaling (33). 
Formation of matrix contacts triggers the assembly of an adhesome complex, and the 
activation of pro-migratory, proliferative, and anti-apoptotic signaling pathways. These 
pathways allow sustained cell survival; therefore, integrin adhesion has been implicated 
in the development of a wide range of pathologies, including tumor cell invasion and 
metastasis (33).  
ITGA11 
ITGA11 is one of the four alpha subunits that heterodimerize with ITGB1 to 
recognize collagen. ITGA11 was originally cloned by the Gullberg lab and found to be 
highly expressed in the adult uterus, heart and skeletal muscle, and localized to focal 
adhesions in fibroblasts (34). Like ITGA2, ITGA11 shows preferential binding to fibrillar 
collagens, recognizing the GFOGER sequence of type I collagen through the alpha-I 
domain (35). The binding of ITGA11 to collagen is Mg2+ dependent, and sensitive to 
concentrations of Ca2+ (35). ITGA11-/- mice are viable and fertile, though they display 
dwarfism and increased mortality, when unchallenged (36). The mice have mutant incisors 
which could contribute to the dwarfism, though the phenotype is shown before weaning 
and is not rescued by feeding soft food. This suggests the growth defect cannot be fully 
contributed to the incisor defect. Mouse embryonic fibroblasts (MEFs) isolated from 
ITGA11-/- mice demonstrate impaired adhesion and spreading on collagen along with a 
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decreased ability to reorganize and retract collagen gels (36). In wound healing studies, 
ITGA11-/- mice exhibit deficiencies in granulation tissue formation and wound contraction, 
possibly caused by impaired myofibroblast differentiation and collagen remodeling (37). 
In the periodontal ligament, sirius red staining indicated an increase in collagen 
accumulation in ITGA11-/- mice, though no change mRNA expression of collagen type I 
or III was observed (36). Interestingly, MT1-MMP (MMP14) mRNA was decreased in 
ITGA11-/- mice, and it has been previously shown that MMP14-/- mice display similar, 
though more extreme, phenotypes such as dwarfism and collagen remodeling deficiencies 
(36, 38, 39). 
 Recently, ITGA11 has been associated with promotion of tumor cell invasion 
through both increased expression in tumor cells and cancer associated fibroblasts (CAFs) 
in the tumor microenvironment. Independent studies have found ITGA11 is one of the 
most highly upregulated genes in non-small cell lung carcinoma (NSCLC) (40, 41). More 
recently however, gene expression analysis has shown ITGA11 is also upregulated in the 
CAFs in NSCLC compared to normal lung fibroblasts (42). Furthermore, xenografts of 
NSCLC in the lungs of ITGA11-/- SCID mice demonstrated impaired metastatic potential 
compared to xenografts in ITGA11+/+ SCID mice, demonstrating the contribution of 
stromal ITGA11 during tumor progression (43). These data suggest an involvement of 
ITGA11 in tumor progression in NSCLC. 
 ITGA11 has also been implicated in breast cancer, where the mode of cancer 
dissemination has been studied in detail. Breast cancer cells are known to utilize collective 
cell invasion to migrate through the normal tissue, where leader cells make contact with 
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the ECM and degrade it in an MMP-dependent manner. Follower cells trail the leader 
cells, traveling along the tracks in the ECM created by the leader cells. In breast cancer, 
ITGA11 was found to be a marker of leader cells, and knockdown of ITGA11 attenuated 
breast cancer cell invasion through a collagen type I and matrigel mixture (44). The 
expression of ITGA11 within gliomas has not been investigated, nor has a role for ITGA11 
been demonstrated in glioma cell invasion. 
 
MT1-MMP 
Metalloproteinases have been widely-studied in cell migration and invasion.  To 
migrate through surrounding tissue, tumor cells must adopt an invasive phenotype, 
undergo cytoskeletal rearrangements, and become polarized as actin-based lamellipodia, 
filopodia, and nanopodia are projected from the leading edge of cells. These protrusions 
localize signaling molecules, cell surface receptors and matrix metalloproteinases 
(MMPs). The MMPs interact with and degrade the basement membrane and the ECM, 
which can be rich in highly cross-linked type I collagen or fibrin. Translocation of 
proteases to the actin-rich structures allows for localized breakdown of the surrounding 
matrix, and subsequent cell migration through tunnels made in the structural barrier (45).  
These events are precisely coordinated by exogenous factors and intracellular signaling 
pathways, discussed below.  
The matrix metalloproteinase (MMP) family is composed of 26 members that are 
structurally characterized by a pro-peptide domain, a Zn2+ associated catalytic domain, a 
flexible linker peptide, and a C-terminal hemopexin-like (HPX) domain (46, 47).  After 
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cleavage of the pro-domain to activate the latent zymogens, the MMPs function to degrade 
components of the ECM. Following stabilization and conformational changes of 
substrates induced by the C-terminal HPX domain (48), the catalytic domain mediates the 
degradation of the target protein. Six of the family members, termed membrane-type 
MMPs (MT-MMPs), contain a transmembrane domain, allowing these proteases to tether 
to the plasma membrane, creating a short cytoplasmic tail domain.  The remaining MMPs 
are soluble and secreted from the cell to degrade substrates beyond the cell membrane. 
The MMPs are further classified by the ECM substrates they are able to hydrolyze, 
including collagen, fibrin, laminin, fibronectin, gelatin, and stromelysin (49, 50).   
Early work investigating the role of MMPs in tumor progression focused on the 
role of soluble MMPs. MMP-2 (also known as gelatinase-A) was previously implicated 
as an essential protease in cell migration and reported to play a leading role in invasion by 
complexing with the v3 integrin at the cell surface, mediating directed migration (51).  
When MMP-2 and MMP-3 were overexpressed in mammary epithelial cells, the normally 
non-invasive cells underwent an epithelial to mesenchymal transition (52). While soluble, 
or secreted MMPs are important for the degradation of denatured type I collagen and other 
substrates, later studies of MT-MMPs have revealed this membrane-bound class is 
indispensable for cell invasion events. MMP-14 or membrane-type 1 matrix 
metalloproteinase (MT1-MMP) has been the most well studied MMP and is essential for 
invasion through a 3D ECM (53). To compare the necessity of soluble versus membrane-
anchored MMPs during invasion, fibroblasts null for MT1-MMP, MMP-2, 3, 8, 9, 13, or 
TIMP-2 were cultured on type I collagen or chicken chorioallantoic membrane (CAM). 
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All mutant fibroblasts, except those lacking MT1-MMP, were able to degrade collagen 
and invade the CAM at similar rates as wild-type fibroblasts. The MT1-MMP null 
fibroblasts demonstrated no collagen degradation or invasion, demonstrating the particular 
importance of MT1-MMP during invasion through collagen (54). Similarly, while CHO-
K1 and MDCK cells are normally invasion-incompetent, when transfected with MT1-
MMP, MMP-1, 2, 7, 9, 11, or 13 and cultured on fibrin matrices with 10% serum, scatter 
factor, and hepatocyte growth factor, all cells were able to degrade fibrin; however, only 
MT1-MMP transfected cells exhibited a gain-of-function phenotype and were able to 
invade the fibrin matrix (55). To further implicate MT1-MMP as the critical MMP, tissue 
explants and microvascular endothelial cells were isolated from mice null for MT1-MMP, 
MMP-2 or -9. The MMP-2 and -9 null endothelial cells and explants were 
indistinguishable from wild-type, forming neovessels and invading collagen matrices in 
culture (56). However, neovessel formation and collagenolysis were inhibited in MT1-
MMP null tissue explants and microvascular cells (56), indicating that MT1-MMP was 
needed for endothelial cells to remodel and invade the ECM. While MMP-2 null mice 
exhibited no developmental or physical defects (56), MT1-MMP gene disruption led to 
abnormalities in osteogenesis, angiogenesis, and collagen turnover leading to reduced 
neovessel formation, dwarfism, arthritis and premature death (38, 57). Altogether, these 
experiments point to a critical role for MT1-MMP in cell invasion of the ECM. 
Various post-translational modifications direct trafficking of MT1-MMP to the 
plasma membrane, including furin cleavage, phosphorylation, and O-glycosylation. The 
pro-domain of the MT1-MMP zymogen contains two recognition sequences for the 
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proprotein convertase furin, which activates MT1-MMP through cleavage at Tyr112 (58, 
59). The MT1-MMP zymogen is a 63 kDa protein and when activated through pro-domain 
cleavage, it is converted to 60 kDa. During endothelial cell sprouting angiogenesis, a 
process analogous to tumor and fibroblast cell invasion, the pro-angiogenic phospholipid, 
sphingosine 1-phosphate, S1P, triggered the migration of MT1-MMP to the plasma 
membrane by activating the G-protein coupled receptors S1P1 and S1P3 (60). S1P 
stimulated Src kinase-mediated phosphorylation of tyrosine residue 573 on the 
cytoplasmic tail of MT1-MMP (61) and induced colocalization between MT1-MMP and 
the adaptor protein p130Cas at the leading edge of the cell (62).  Src-dependent Tyr573 
phosphorylation on the cytoplasmic tail of MT1-MMP was shown to be essential for cell 
migration. Additionally, O-glycosylation of the hinge domain regulates the stability of 
MT1-MMP through the inhibition of both autolysis and internalization of the active form 
of the enzyme (63). While only the transmembrane domain was essential for localization 
to the cell surface, the cytoplasmic domain was critical in the localization of MT1-MMP 
to the leading edge of the plasma membrane (64, 65). To test for MT1-MMP localization 
in vivo, mice heterozygous for an MT1-MMP allele containing a LacZ reporter gene were 
generated (66). In tissue explants cultured on type I collagen matrices, β-gal activity was 
preferentially localized to the invading endothelial tip cells (66).  Thus, proper post-
translational modifications direct MT1-MMP to the cell surface to facilitate successful 
invasion events.  
The proteolytic activity of MT1-MMP is coordinated with integrins and receptor 
tyrosine kinases. Cell migration and invasion requires cleavage of the ECM, which 
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presents a structural barrier consisting of cross-linked type I collagen networks and other 
substrates (67). MT1-MMP hydrolyzes collagen type I, II, III, proteoglycan, fibronectin, 
vitronectin, type 1 gelatin, the alpha chain of laminin-1, the gamma-2 chain of laminin-5, 
integrins, and cell surface receptors (61, 68-70). Following the degradation of type I 
collagen by MT1-MMP, cryptic binding sites for the αvβ3 integrin are exposed (71, 72). 
The αvβ3 integrin binds to the ECM and associates with the tyrosine kinase receptor 
VEGFR-2, leading to increased migration in endothelial and other invasive cells (73, 74).  
Thus, matrix proteolysis through MT1-MMP may allow complex formation between 
integrins and receptor tyrosine kinases, which work together to facilitate invasion. In 
endothelial cells, MT1-MMP complexes with the 21 integrin to promote endothelial 
cell assembly into interconnected networks in 3D collagen matrices (75). 
 
CELL INVASION 
Cell invasion into surrounding tissue requires coordinated matrix adhesion, 
remodeling, and degradation (76). A critical component of cell invasion is the integration 
of signals between the extracellular environment and the cell cytoskeleton. These 
bidirectional signals are controlled by ligation of integrins to proteins in the basement 
membrane and extracellular matrix (ECM). Integrin activation and clustering lead to the 
recruitment of actin binding proteins, such as talin and paxillin, to the sites of matrix 
adhesion, forming focal adhesions and connecting the actin cytoskeleton to ECM. Many 
signaling molecules and pathways are activated downstream of integrin activation and 
focal adhesion formation, including Src, FAK, the family of small Rho GTPases, and the 
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PI3K and MAPK signaling pathways. Activation of small Rho GTPases, Rac and Cdc42, 
causes dynamic actin remodeling to form protrusive actin-based pseudopodia into the 
surrounding matrix (77, 78). After formation of these adhesive protrusions, matrix 
proteases, such as MT1-MMP, are activated and recruited which allows directed 
proteolysis (79, 80). MT1-MMP has been shown to complex with integrins within these 
adhesive sites where it proteolyzes matrix proteins in a controlled manner (81-83). This 
matrix degradation allows for coordinated proteolysis, cell motility into the space created 
through ECM degradation, and also reveals cryptic sites in the ECM proteins and a 
reservoir of signaling molecules trapped within the matrix which promote invasion (84-
87). As the leading edge of the cell migrates through the surrounding tissue, integrins bind 
to the newly exposed matrix, creating focal adhesions and sending additional actin-based 
protrusions to examine the nearby environment. Concomitantly, the rear of the cell 
releases its adhesions to the ECM by cleaving the cytoplasmic integrin tails attached to 
the ECM through calpain activity or by decreasing the integrin affinity for the ECM 
substrate (88, 89). 
Pseudopodia and other actin-based degradative structures are common 
characteristics of more motile and invasive cells (90, 91). Formation and maturation of 
pseudopodia is dependent on attachment of integrins to the ECM (92), and inhibition of 
pseudopodia formation attenuates tumor cell migration and invasion in several tumor cell 
lines, including the U87 glioblastoma cell line (93). Further, many of the proteins known 
to localize to focal adhesions and pseudopodia, such as Arp2/3, fascin, cortactin, and 
alpha-actinin, are upregulated in cancer (94, 95). Although pseudopodia are linked with 
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tumor progression, a role for noncanonical NF-B signaling in the development of 
pseudopodia has not been established. 
 While the mechanism of cell invasion described above is considered to be utilized 
during single cell tumor cell invasion, tumor cells can employ various mechanisms to 
invade collectively through their respective surroundings (96). Tumors are made up of a 
heterogeneous population of cells, and not all within the tumor are capable of degrading 
and invading their surrounding matrix. One mode tumors can use to overcome this barrier 
is through collective invasion. In some ways analogous to endothelial cell tip and stalk 
cell relationships during angiogenesis, in collective cell invasion, a cell with an invasive 
phenotype degrades the matrix and invades while the cells which are not capable of 
degrading the matrix follow behind (97). Although not proliferative, leader cells are 
invasion-competent and proteolyze the ECM in an MMP-dependent manner (98, 99). The 
follower cells, while proliferative, cannot degrade the matrix and thus cannot invade 
through the surrounding barrier. These populations can form a commensal relationship 
where the leader cells degrade the matrix and invade, leaving a tunnel in the matrix which 
the follower cells can migrate through in an MMP-independent manner. It has been 
suggested that the follower cells could actually be the population which colonizes the sites 
of metastasis (44). This mode of collective invasion has been found to be utilized in breast 
cancer (44, 100), melanoma (101), colon cancer (102), glioblastoma (103), and during 
neural crest development (104, 105).  
To study cell invasion, we utilize a 3D in vitro assay where tumor cells isolated 
from glioblastoma patient tumors are seeded onto a polymerized 3D type I collagen matrix 
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(29, 127). Though not normally expressed in the brain, type I collagen has been found to 
be a prominent component of the glioma ECM (107). To mimic the properties of the in 
vivo ECM, the collagen is reconstituted using acid which preserves the collagen 
telopeptides, allowing fibril formation and crosslinking, creating a matrix requiring MMP-
dependent degradation for cell invasion (108, 109). We have shown previously that glioma 
cells invade this matrix in a MMP-dependent manner (30). In these studies, we use this 
model system to investigate mechanisms through which noncanonical NF-B signaling 
regulates glioma cell invasion. 
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CHAPTER II  
NIK REGULATES MT1-MMP ACTIVITY AND PROMOTES GLIOMA CELL 
INVASION INDEPENDENTLY OF THE CANONICAL NF-B PATHWAY* 
SUMMARY  
A growing body of evidence implicates the noncanonical NF-B pathway as a key 
driver of glioma invasiveness and a major factor underlying poor patient prognoses. Here, 
we show that NF-B-inducing kinase (NIK/MAP3K14), a critical upstream regulator of 
the noncanonical NF-B pathway, is both necessary and sufficient for cell-intrinsic 
invasion, as well as invasion induced by the cytokine TWEAK, which is strongly 
associated with tumor pathogenicity. NIK promotes dramatic alterations in glioma cell 
morphology that are characterized by extensive membrane branching and elongated 
pseudopodial protrusions. Correspondingly, NIK increases the phosphorylation, 
enzymatic activity and pseudopodial localization of membrane type-1 matrix 
metalloproteinase (MT1-MMP/MMP14), which is associated with enhanced tumor cell 
invasion of three-dimensional collagen matrices. Moreover, NIK regulates MT1-MMP 
activity in cells lacking the canonical NF-B p65 and cRel proteins. Finally, increased 
expression of NIK is associated with elevated MT1-MMP phosphorylation in orthotopic 
xenografts and co-expression of NIK and MT1-MMP in human tumors is associated with 
__________________ 
*Part of this research was originally published in the journal Oncogenesis. Duran CL, Lee 
DW, Jung JU, Ravi S, Pogue CB, Toussaint LG, Bayless KJ, Sitcheran R (2016). NIK 
regulates MT1-MMP activity and promotes glioma cell invasion independently of the 
canonical NF-B pathway. Oncogenesis. 2016. 5(6):e231. © Nature Publishing Group. 
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poor glioma patient survival. These data reveal a novel role of NIK to enhance 
pseudopodia formation, MT1-MMP enzymatic activity, and tumor cell invasion 
independently of p65. Collectively, our findings underscore the therapeutic potential of 
approaches targeting NIK in highly invasive tumors.  
INTRODUCTION  
The persistent invasiveness of high-grade glioma cells into healthy brain tissue is 
a major factor underlying the therapy resistance and poor prognosis of this malignancy. 
NF-B transcription factors have been shown to play key roles in regulating tumor-
promoting functions including cell migration and invasion (110, 111). There are two main 
pathways controlling NF-B activation. In the context of glioma, most studies have 
focused on the canonical NF-B pathway, which is dependent on IB Kinase- (IKK) 
and mediated by p65 (RELA)- or cRel (REL)-containing transcription factor complexes. 
However, we and others have demonstrated that constitutive, noncanonical NF-B 
signaling, mediated by RelB-p52 complexes, predominates in aggressive, mesenchymal 
glioma where it promotes cell migration, invasion and tumor recurrence (11, 29, 30, 112). 
Activation of the noncanonical NF-B pathway is dependent on NF-B-inducing kinase 
(NIK, also known as MAP3K14), a constitutively active kinase that is continuously 
targeted for proteasomal degradation in unstimulated cells (17-19). In response to specific 
cytokines, NIK degradation is attenuated, resulting in activation of IKK, 
phosphorylation-dependent proteolytic processing of the RelB-inhibitory protein p100 to 
p52, and nuclear translocation of RelB-p52 heterodimers (20). We have recently shown 
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TNF-like weak inducer of apoptosis (TWEAK, also known as TNFSF12) preferentially 
activates noncanonical NF-B RelB and p52 proteins and promotes the invasive properties 
of glioma cells (30).  
Tumors must degrade the surrounding extracellular matrix (ECM) to invade into 
nearby healthy tissue (113). Invasive cancer cell phenotypes show elevated formation of 
invadopodia, which are specialized actin- and cortactin-rich membrane protrusions that 
mediate attachment to and degradation of the ECM (79). Invadopodia formation in 2D is 
associated with greater invasive behavior in 3D, where cells must extend larger 
protrusions, termed pseudopodia, to migrate successfully (98, 114). Membrane type-1 
matrix metalloproteinase (MT1-MMP, also known as MMP-14), is the predominant 
ECM-degrading enzyme localized to invadopodia (98, 113, 114). MT1-MMP is highly 
expressed in invasive human cancers and is associated with poor patient survival (115-
118). MT1-MMP is activated by furin cleavage (119, 120), and once phosphorylated on 
Y573 (121), MT1-MMP is directed to the plasma membrane (122), where it can degrade 
multiple ECM proteins (123).  Notably, the signals that regulate MT1-MMP localization 
to the cell surface during invasion are not fully understood.  
Several studies have established a role for canonical NF-B-dependent (p65-
mediated) regulation of MT1-MMP expression (124, 125). In addition, Fritz and 
colleagues demonstrated that noncanonical NF-B signaling (RelB-p52-mediated) 
regulates MT1-MMP expression and tumor cell invasion induced by the scaffold protein 
CNK1 (126). Thus, while both canonical and noncanonical NF-B signaling have been 
linked to regulating MT1-MMP expression, whether these pathways control activation and 
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localization of MT1-MMP during invasion have not been established. Importantly, the 
role of NIK in both constitutive and TWEAK-induced invasion of glioma cells is not well 
understood. In this study, we establish novel functions for NIK in regulating MT1-MMP.  
MATERIALS AND METHODS 
Reagents 
TNFα was obtained from Promega (Madison, WI), rhTWEAK was purchased 
from PeproTech (Rocky Hill, NJ), TAPI-2 was obtained from Calbiochem (San Diego, 
CA). MG132 was purchased from Cell Signaling Technology (Danvers, MA). Collagen 
type I was isolated and prepared as previously described (127) or purchased from Corning 
(Corning, NY). 
 
Cells and culture conditions 
BT25 and BT114 cell lines were obtained from human glioma patients and 
described previously (128). Glioma lines were maintained as tumorspheres in Neural Stem 
Cell (NSC) medium (DMEM/F12, 1x B-27 Supplement minus Vitamin A, 1x Glutamax, 
50 ng/ml EGF, 50 ng/ml bFGF, 1x Pen/Strep). Spontaneously immortalized mouse 
embryonic fibroblasts (MEFs) from p65-/-, cRel-/-p65-/- animals and their corresponding 
WT MEFs were a kind gift from Dr. Albert S. Baldwin Jr. (UNC, Chapel Hill), RelB+/+ 
and RelB-/- MEFs were generously provided by Dr. Denis Guttridge (The Ohio State 
University), and NIK+/+ and NIK-/- MEFs were obtained from Dr. Robert Schrieber 
(University of Washington). HEK293FT cells were purchased from Invitrogen (Grand 
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Island, NY). MEF and HEK293FT cells were cultured in DMEM+10% FBS (Invitrogen). 
All cells were incubated at 37°C with 5% CO2. 
 
Constructs 
pLenti6 overexpression constructs for NIK were generated by subcloning cDNA 
into pLenti6-V5-DEST (Addgene, Cambridge, MA) using the GATEWAY™ Cloning 
System. Luciferase (Promega, Madison, WI) coding sequences were subcloned into 
pLenti6-V5-DEST and used as controls for NIK overexpression. NIK(S867A) mutation 
was obtained by PCR cloning using oligo primers containing the mutation.  
 
CRISPR-Cas9 NIK gene knockout cell clones 
Lenti-CrispR-v2 (Addgene, Cambridge, MA) was used to express both Cas9 and 
human NIK sgRNA (sgNIK-1: GCUCCUUCGGAGAGGUGCAC, sgNIK-2: 
GAAAGCGUCGCAGCAAAGCC, or sgNIK-3: AGUACCGAGAAGAAGUCCAC).  
BT25 cells were transduced with mixture of lentiviruses carrying these sgRNAs then 
selected against 0.6 μg/ml puromycin. 1507 bp and 33 bp deletions around sgRNA target 
sequences were identified by sequencing and loss of NIK expression was confirmed by 
immunoblot, qPCR and/or immunofluorescence microscopy analysis of puromycin-
resistant cells. Single colony cells were isolated by serial dilution and experiments were 
repeated with at least two clones.  
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Lentiviral production 
HEK293FT cells were transfected with 24 μg of lentiviral plasmids using 72 μg of 
polyethyleneimine (Polysciences Inc., Warrington, PA). Lentiviruses were harvested after 
three days and used to infect 2x105 BT114 or MEF cells. Transduced cells were grown for 
72 hours in NSC medium or DMEM with 10% FBS containing 6 μg/ml or 0.1 μg/ml 




Invasion assays were established as previously described (127). Briefly, 3D 
collagen type-I matrices were prepared at a final concentration of 2 mg/ml, containing 
indicated concentrations of TWEAK (0 or 10 ng/ml). Following collagen polymerization, 
dissociated cells (40,000 cells/100 μl DMEM) were seeded and incubated at 37°C with 
5% CO2. To inhibit MMPs, DMSO, 2.5 or 5 μM TAPI-2 was preincubated with the cells 
for 20 minutes at 37°C. Cells, combined with the inhibitors, were seeded onto collagen 
matrices. Invasion assays were fixed after 24-48 hours incubation, as indicated, with 3% 
glutaraldehyde in PBS and stained with 0.1% toluidine blue in 30% methanol.  
 
Quantification of invasion responses 
Invasion density was quantified manually in toluidine blue-stained invasion assays 
as the average number of structures invading past the monolayer, per field, using an 
eyepiece fit with a 10x10 ocular grid. At least four wells per treatment group were counted, 
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per experiment, for three independent experiments. To visualize invasion responses, after 
fixation and staining, collagen gels were removed from the well, cut and imaged from the 
side using an Olympus CKX41 microscope with a Q-Color 3 camera or a Nikon Ti Eclipse 
inverted microscope and DS-Fi1 5-Meg Color C-Mount Camera at 20x magnification.  
 
RNA isolation, cDNA synthesis, and quantitative-RT-PCR 
Total RNA was isolated from cells using PurelinkTM RNA Mini Kit (Life 
Technologies). cDNA was synthesized from 1 μg of total RNA using Super-Script® III 
Reverse Transcriptase (Life Technologies) following manufacturer’s instructions. 
Quantitative RT-PCR was performed using SYBR® Green PCR Master Mix (Applied 
Biosystems, Foster City CA). Expression of mRNA was normalized to either GAPDH or 
RPLP0 expression levels. The following primers were used: GAPDH 5′-
AATGAAGGGGTCATTGATGG-3′, 5′-AAGGTGAAGGTCGGAGTCAA-3′; RPLP0 
5′- TCGTCTTTAAACCCCTGCGTG-3′, 5′-TGTCTGCTCCCACAATGAAAC-3′; 
MMP-14 (human) 5′-TGCCTACCGACAAGATTGATG-3′ 5′-
ATCCCTTCCCAGACTTTGATG-3′; MMP14 (mouse) 5’-
GGATGGACACAGAGAACTTCG-3’ 5’-TTTTGGGCTTATCTGGGACAG-3; NIK 5′-
TTCAGCCCCACCTTTTCAG- 3′ 5′-ACGCTTTCCCTTCCAACAC-3′. Three 
independent experiments were performed in triplicate wells. qRT-PCR data was analyzed 
using StepOne Software (version 2.1). ΔΔCT values were normalized to GAPDH 
expression values for each sample, set relative to indicated treatment, and converted to 2-
ΔΔCT to compare the relative mRNA fold change expression between treatment groups.  
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Immunostaining 
2.5x105 cells were seeded on collagen (50 μg/ml) coated 12 mm coverslips in a 24 
well plate. After 16 hours incubation, cells were treated as indicated, fixed in 4% 
paraformaldehyde, permeabilized with 0.5% Triton X-100 in PBS, and blocked overnight 
in 0.1% Triton X-100, 1% BSA/1% goat serum in TBS at 4°C. To examine the effects of 
TWEAK treatment on pMT1-MMP localization in MEFs, cells were serum-starved for 2 
hours, treated with TWEAK (10 ng/ml) for 4 hours and subsequently fixed and processed 
as described above. 1.09 μM DAPI (Invitrogen) was used for staining nuclei and the 
following primary antibodies were used: cortactin (Upstate, Lake Placid, NY, 05-180), 
p65 (SC-8008), custom generated Y573 pMT1-MMP (21st Century Biochemicals, as 
previously described (121), NIK (Abcam, Cambridge, MA, ab7204), and either Alexa 
Fluor 488 Phalloidin (Invitrogen, A12379) or Alexa Fluor 647 Phalloidin (Invitrogen, 
A22287). Cells were imaged using a Nikon TI A1R inverted confocal microscope to 
capture Z-stacked images with a 0.225 μm step size. Fluorescence was quantified using 
Nikon Elements Software (see Figure 6B). 
 
MT1-MMP activity assays 
MT1-MMP activity assays were performed on cell lysates (not conditioned media) 
using a Sensolyte, AS-72025 kit, with several modifications; to inhibit soluble MMPs and 
specifically evaluate MT1-MMP activity after 8-24 hours invasion, lysates from cells 
invading collagen were incubated with conditioned media collected from TIMP-1-
transfected HEK293FT cells (129). The MT1-MMP sensitive substrate was added to equal 
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amounts of cell lysate and incubated for 30 minutes. Fluorescence intensity was measured 
at Ex/Em 490/520 nm using Victor X3 Multilabel Reader 2030. Relative fluorescence 
units (RFUs) were calculated by subtracting the control reading from each sample and 
averaging the remaining RFU value of the replicates. Gelatin zymography was performed 
as previously described (130). 
 
Western blotting 
Whole cell extracts were prepared using RIPA. To detect NIK protein expression, 
cells were pre-treated with 5 μM MG132 for 1 hour and with or without 10 ng/ml TWEAK 
for 5 hours, as indicated. Proteins were subjected to western blotting as previously 
described (30, 129), using the following specific antibodies: α-Actin (Calbiochem, CP01), 
MT1-MMP (Millipore, MAB3328), pMT1-MMP (Y573) NIK (CST-4994), p65 (SC-
8008), p-p65 (Ser536, CST-3033), RelB (SC-226), p100/p52 (CST-4882), and GAPDH 
(Abcam, ab8245).  
 
Immunohistochemical analysis of mouse xenograft tissue 
Intracranial xenografts were previously performed (30). Animals from that 
experiment were perfused, brains were removed and ﬁxed with 4% paraformaldehyde and 
embedded in OCT. 10 μm-thick sections were immunostained with incubated with NIK-
specific antibody (Abcam, ab7204) and Alexa Fluor® 488-secondary antibody 
(Invitrogen, A-11008) and DAPI mounting media (Invitrogen). Images were acquired 
using a Nikon TI A1R inverted confocal microscope. Adjacent tumor sections were used 
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for immunohistochemical detection of pMT1-MMP (Y573) using the Vectastain ABC 
elite kit (Vector Laboratories). The signal was developed using DAB peroxidase substrate 
(Vector Laboratories), counterstained with haematoxylin and images were acquired on the 
Nikon Eclipse Ti microscope. 
 
Ex vivo glioma tumor tissue staining 
The use of de-identified human glioblastoma tissue was approved by the 
Institutional Review Boards (IRBs) of Saint Joseph Regional Health Center, Bryan, TX 
(IRB2012-001), and Texas A&M University (IRB2014-0318D). Sections of human 
glioma biopsy samples were stained with DAPI and antibodies specific for pMT1-MMP 
(Y573) and NIK (Abcam, ab7204). NIK-ab7204 was pre-conjugated to AF488 using an 
antibody labeling kit (Molecular Probes®/Invitrogen, A20181) and immunostaining was 
performed sequentially using the pre-labeled NIK antibody last.  Imaging was performed 
as described above. 
 
Glioma database analysis 
Gene expression data for glioblastoma (GBM) patients from The Cancer Genome 
Atlas (TCGA), Cell 2013 dataset (10) and lower grade glioma (LGG) patients from the 
TCGA (Provisional raw data set, NCI) were downloaded from cBioPortal for Cancer 
Genomics (131, 132) and analyzed using Prism 6 (Graphpad Software, Inc.). Kaplan-
Meier plots were generated from GBM and LGG patients with increased NIK (MAP3K14) 
and MT1-MMP (MMP14) mRNA expression with a z-score of 1.5. GBM dataset can be 
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All statistical analyses were performed using Prism 6 (Graphpad Software, Inc.). 
Student’s t-test was performed on data comparing two samples, unless otherwise 
indicated. One-way or two-way ANOVA with Holm-Šídák or Tukey’s Honest Significant 
Difference (HSD) post-hoc test for comparing multiple samples. Kruskal-Wallis with 
Dunn’s post-test was used to assess statistical significance between log2-base NIK and 
MT1-MMP gene expression data. For ANOVA analyses, multiplicity adjusted P-values 
are reported (133) with significance value of alpha =0.05. Survival and disease free patient 
data was analyzed using a Log-rank Mantel-Cox test. Unpaired Welch t-test was used to 
analyze mean survival GBM patients. No statistical method was used to predetermine 
sample size. Experiments were not randomized. The investigators were not blinded to 
sample allocation during experiments. 
RESULTS  
NIK is required for constitutive and TWEAK-induced glioma cell invasion 
We previously demonstrated that patient-derived glioma cell lines exhibit distinct 
invasive potentials that correlate more strongly with noncanonical NF-B/RelB signaling 
than with canonical NF-B/p65 activity (29, 30). To address the role of NIK, a key 
upstream regulator of noncanonical NF-B signaling, in glioma invasion and 
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pathogenesis, we first sought to determine whether NIK was sufficient to promote cell 
invasion in BT114 glioma cells, which exhibit low invasive activity (30). In addition to 
expressing wild-type NIK (NIK(WT)), which is continuously degraded under 
unstimulated conditions, we also used a more stable form of NIK that allowed greater 
protein accumulation and facile immunological detection. Specifically, a S867A 
substitution at the conserved TBK1 phosphorylation site renders human NIK resistant to 
degradation (17), and immunoblot analysis of BT114 glioma cells confirmed that 
NIK(S867A) is expressed at higher levels than NIK(WT) (Figure 1A). Using 3-
dimensional (3D) collagen type I invasion assays, we observed that NIK transfected cells 
were more invasive than controls cells, and NIK(S867A) exerted a significantly stronger 
effect than NIK(WT) (Figure 1B and C). Furthermore, ectopic expression of NIK in 
several additional glioma lines, including BT116, U87, and BT25 cells, promoted cell 
invasion in this assay (Figure 2). 
Next, we investigated the effects of NIK knockdown using CRISPR/Cas9/small-
guide (sg)RNA-mediated deletion of NIK. For these experiments we took advantage of 
the highly invasive BT25 glioma line (30). NIK protein is no longer detectable in both 
untreated and TWEAK-treated BT25-sgNIK cells, indicating efficient sgRNA-mediated 
deletion of NIK (Figure 3A). We also confirmed loss of NIK expression in BT25-sgNIK 
cells by immunofluorescence staining, flow cytometry and impaired p100 processing and 
p52 nuclear localization (Figure 4A-C). Importantly, loss of NIK significantly diminished 
the invasive potential of both untreated, as well as TWEAK-treated, BT25-sgNIK cells 
(Figure 3B and C). Similarly, loss of NIK in BT114-sgNIK cells significantly attenuated 
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invasion in unstimulated and TWEAK-treated cells (Figure 5A-C).  Together, these data 
identify a critical role for NIK in regulating both constitutive and TWEAK-induced glioma 
























Figure 1. NIK promotes glioma cell invasion.  
(A) Western blot analysis of BT114 glioma cells transduced with lentiviral vectors expressing 
luciferase (Control), NIK(WT) or NIK(S867A). Whole cell detergent lysates were probed with 
indicated antibodies.  (B) Side-view images of BT114-Control, -NIK(WT) and -NIK(S867A) cells after 
24 hours invasion in 3D collagen matrices. Cells in collagen matrices were fixed, stained with toluidine 
blue, cut into thin slices and imaged with light microscopy. Scale bar = 50 µm. (C) Quantification of 
invasion density of BT114-Control, -NIK(WT) and -NIK(S867A) cells in (B) represented as the 
average numbers of invading cells per 1-mm2 field (top-view) ± SD after 24 hours of invasion. At least 
6 wells were quantified per experiment for four independent experiments. Graph shows a representative 
experiment. Statistical significance was calculated with 2-way ANOVA and Tukey’s HSD post test. 
Multiplicity adjusted P-values:  * 0.0109 for Control vs. NIK(WT) and **** <0.0001 for Control vs. 
NIK(S876A).  
 

















Figure 2. NIK promotes invasion in different glioma lines. 
(A) BT116 cells expressing vector (Control) or NIK(WT) were seeded onto 3D collagen matrices and 
allowed to invade 24 hours. Graph shows average number of invading cells +/- SD in a 0.25 mm2 field. 
At least 4 wells were quantified per cell type for three independent experiments. Unpaired t-test P-
value: ** 0.0037 Control vs. NIK(WT). Western blot analysis of BT116 cells expressing vector 
(Control) or NIK(WT) confirming exogenous NIK expression. (B) U87 cells expressing vector 
(Control) or NIK(WT) were seeded onto 3D collagen matrices and allowed to invade 24 hours. Graph 
shows average invasion density. At least 4 wells were quantified per cell type for three independent 
experiments. Unpaired t-test P-value: ** 0.0012 Control vs. NIK(WT). Western blot analysis of U87 
cells expressing vector (Control) or NIK(WT) confirming exogenous NIK expression. (C) BT25 cells 
expressing NIK under control of reverse tetracycline- controlled transactivator (rtTA), inducible 
through doxycycline, were not treated (-Dox) or treated with 5ng/ml (+Dox) for 48 hours before seeding 
onto collagen matrices and allowing to invade 48 hours. Graph shows average invasion density. At 
least 4 wells were quantified per cell type for three independent experiments. Unpaired t-test: ***P 
<0.0001 -Dox vs. +Dox. Western blot analysis of BT25 cells treated with (+Dox) or without 
doxycycline (-Dox) confirming induced NIK expression.  
 



























Figure 3. NIK knockout attenuates glioma cell invasion.  
(A) Western blot analysis of whole cell lysates from BT25-Control and clonally selected BT25-sgNIK 
cells. Cells were first treated with MG132 for 1 hour to prevent NIK degradation and then untreated, 
or treated with TWEAK (10 ng/ml), as indicated for 5 hours. Extracts were probed with indicated 
antibodies.  (B) Side view images of invasion assays with untreated or TWEAK-treated (10 ng/ml) 
BT25-Control and BT25-sgNIK cells allowed to invade 3D collagen matrices for 24 hours. Scale bar 
= 100 μm.  (C) Invasion densities for (B) were quantified as described above in (1C), quantifying at 
least 3 wells of invading cells were quantified per experiment for three independent experiments. Graph 
shows a representative experiment.  Different letters represent statistically significant differences 
calculated with two-way ANOVA and Tukey’s HSD post test. Multiplicity adjusted P-values for all 
differences is <0.0001.  
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NIK promotes pseudopodia formation 
Because changes in morphology can be predictive of cell motility and metastatic 
potential (134), we sought to determine whether the ability of NIK to promote invasion of 
glioma cells was associated with changes in cell shape. Examination of BT114 cells in 2D 
culture revealed that both NIK(WT) and NIK(S867A) significantly altered cell 
morphology, specifically by inducing the formation of F-actin- and cortactin-dense, 
branched cellular processes resembling the pseudopodia of invasive cells (Figure 6A). 














Figure 4. Glioma cells expressing sgNIK have decreased NIK expression. 
(A) Nuclear and cytoplasmic fractions were isolated from BT25 cells expressing vector (Control) or 
sgNIK treated with (+) or without (-) 10 ng/ml TWEAK for 24 hours. Extracts were probed with 
antibodies directed to Actin and p100/p52 to assess p100 processing and p52 nuclear translocation 
downstream of NIK. (B) BT25-Control and BT25-sgNIK cells were seeded onto collagen coated 
coverslips and immunostained with antibodies directed to NIK (green) and DAPI (blue) to demonstrate 
loss of NIK expression in sgNIK cells, and specificity of antibody. Scale bar = 10 μm. (C) Flow 
cytometry was performed to quantify NIK staining in BT25-Control and BT25-sgNIK cells. 3x105 cells 
were fixed, permeabilized in 0.3% Triton in PBS, and incubated with antibodies directed to NIK or 
isotype controls followed by incubation with FITC-conjugated secondary antibody. At least 10000 
events were analyzed with a BD LSRFortessaTM X-20 cell analyzer and data was analyzed, 
normalizing to mode, with FLowJo software (v-X).  
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length of extended pseudopodial cell processes were increased in both NIK(WT) and 

























Figure 5. Cells expressing sgNIK do not invade in response to TWEAK.  
(A) BT114-Control and BT114-sgNIK cells were seeded onto collagen matrices with or without 10 
ng/ml TWEAK and allowed to invade 24 hours. Representative graph from three independent 
experiments shows average invasion density counted from three wells per treatment. Statistical analysis 
was calculated using 2-way ANOVA and Tukey’s HSD post test. Different letters indicate statistically 
significant differences with the following multiplicity adjusted P-values: p=0.0002 for “a vs. b”; p<0.01 
for “b vs. c” and “a vs. c”. (B) Western blot analysis of BT114 cells expressing vector (Control) or 
sgNIK treated with or without MG132 (5 μM) for 1 hour to prevent NIK degradation and then untreated, 
or treated with TWEAK (10 ng/ml), as indicated for 5 hours. Whole cell lysates were probed with 
indicated antibodies. (C) Western blot analysis of BT114 cells expressing vector (Control) or sgNIK 
treated as in Figure 4A. Extracts were probed with antibodies directed to Actin and p100/p52 to 
demonstrate inhibition of p100 processing and p52 nuclear translocation in BT114-sgNIK cells.  
 

































Figure 6. NIK enhances pseudopodia formation.  
(A) BT114 -Control), -NIK(WT), or -NIK(S867A) cells were seeded onto collagen coated coverslips 
and fixed after 16 hours. Cells were stained with DAPI (blue), Alexa Fluor 488-phalloidin (green), and 
cortactin (red) and imaged using confocal microscopy. Images of representative cells are shown. Scale 
bar = 10 μm.  (B-D) Quantification of cell size and pseudopodial length of BT114 cells in (A). At least 
65 cells (Control, NIK(WT) or NIK(S867A)) from three independent staining experiments were used 
for the following blinded quantifications: (B) Cells were seeded onto collagen-coated coverslips and 
stained with DAPI (blue) and antibodies directed to pMT1-MMP (green), cortactin (red), and Alexa 
Fluor 647-phalloidin (Cy-5). Only single cells containing one nucleus and not in contact with another 
cell were used for quantifications. The average pseudopodial length was then quantified by drawing a 
line starting from the line tangent to the cell body, and extending to the furthest cortactin- pMT1-MMP- 
positive point of the protrusion. The average cell area was quantified by creating an ROI outlining the 
cell. At least 65 protrusions per treatment group were used for blinded quantifications. Scale bar=10 
μm. (C) Average cell size (area, μm2) ± SEM. Statistical significance was calculated with one-way 
ANOVA and Tukey’s HSD post test. Multiplicity adjusted P-values: *** 0.0002 for Control vs. 
NIK(WT);  **** <0.0001 for Control vs. NIK(S867A), (D) Average length (μm) of pseudopodial 
structures extended from the cell body ± SEM. Statistical significance was calculated with one-way 
ANOVA and Tukey’s HSD post test. Multiplicity adjusted p-values: **** <0.0001 for Control vs. 
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Conversely, we observed that BT25-sgNIK cells were smaller and less elongated 
compared with BT25 control cells (Figure 7A-C). These data establish a role for NIK in 





























Figure 7. NIK silencing attenuates pseudopodia formation. 
(A) BT25-Control or BT25-sgNIK cells were treated and imaged as described in (Figure 6A). 
Representative cells shown. Scale bar = 10 μm. 7B and C were quantified as described in Figure 6B. 
(B) Average cell size (area, μm2) ± SEM for BT25-Control or BT25-sgNIK cells. Unpaired t-test P-
value: *0.0330 for Control vs. sgNIK. (C) Average length (μm) of pseudopodial structures extended 
from the cell body ± SEM. Unpaired t-test P-value: *** <0.0002 for Control vs. sgNIK. At least 50 
cells from three independent experiments were used for quantification (Figures 7B, 7C). 
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NIK increases MT1-MMP pseudopodial localization and enzymatic activity  
The matrix-degrading enzyme, MT1-MMP (also known as MMP-14), is the 
predominant proteolytic component of invasive pseudopodia (98, 113, 114). Unlike 
soluble, secreted MMPs, cell surface localization of active, phosphorylated MT1-MMP 
(pMT1-MMP, Y573) is required for degradation of ECM proteins and tumor cell invasion 
(121, 122, 135-137).  We therefore investigated whether NIK promoted pseudopodia 
formation through regulation of MT1-MMP. First, we noted a positive correlation between 
glioma invasion, NIK expression, MT1-MMP expression and MT1-MMP enzymatic 
activity in BT25 and BT114 cells (Figure 8).  We previously demonstrated that MT1-
MMP mRNA levels were not altered by TWEAK treatment (30). Consistent with this 
observation, we found that NIK(WT) does not significantly affect the expression of MT1-
MMP at protein or mRNA level in BT114 cells (Figure 9A, B). MT1-MMP mRNA levels 
are unaltered in BT114-sgNIK cells irrespective of treatment with TWEAK (Figure 9C). 
The increase of MT1-MMP in BT114-NIK(S867A) cells compared with BT114-
NIK(WT) cells is likely due to higher expression levels of transfected NIK in the former 
compared to the latter cells (Figure 9A, B). BT114-NIK(S867A) cells also show slightly 
increased levels of RelB, but total and phosphorylated (P536) p65 levels remain 
unchanged.  However, BT114 cells overexpressing NIK(WT) and NIK(S867A) exhibit 
increased levels of pMT1-MMP (Figure 9A), suggesting a role for NIK in regulating MT1-
MMP localization to invasive pseudopodia.  
We next evaluated the effect of ectopic NIK expression on pMT1-MMP 
subcellular distribution. BT114-Control cells exhibit a punctate pMT1-MMP staining 
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pattern throughout pseudopodial structures at the cell periphery (Figure 10A). When to 
compared to these controls, BT114 cells expressing NIK(WT) or NIK(S867A) showed an 
increase in pMT1-MMP pseudopodial staining, with NIK(S867A) having a stronger effect 
than NIK(WT) (Figure 10A). Quantification of pMT1-MMP staining demonstrated that 
the percent of pMT1-MMP at the pseudopodia is significantly increased in NIK(WT)- and 
NIK(S867A)-expressing cells, and correlates with levels of NIK expression (Figure 10B). 
Volumetric views of these immunostaining experiments demonstrated that pMT1-MMP 
co-localizes with the pseudopodia marker cortactin (Figure 10C), which is required for 
pseudopodia assembly and maintenance (79). Consistent with these observations, we 
observed that MT1-MMP enzymatic activity is increased in cells expressing NIK(WT) or 
NIK(S867A) (Figure 10D). Loss of NIK in BT25-sgNIK cells did not affect expression of 
MT1-MMP mRNA or total protein, but did diminish levels of pMT1-MMP (Figure 11A 
and 4B). Furthermore, we also observed that pseudopodial localization of pMT1-MMP 
was significantly diminished in the absence of NIK (Figure 11C, D). Taken together, both 
gain-of-function and loss-of-function studies support a working model whereby NIK 
predominantly regulates MT1-MMP at the post-transcriptional level.  
 
 





Figure 8. Glioma cell invasiveness correlates with MT1-MMP expression and activity. 
BT25 and BT114 glioma cell lines were seeded onto collagen matrices and allowed to invade 24 hours. 
Cultures were fixed in 3% glutaraldehyde, stained with toluidine blue. (A) Invasion density was 
quantified as the average number of invading cells +SD in a 0.25 mm2 field. At least 4 wells were 
quantified per cell type for three independent experiments. Unpaired Student’s test P-value 
****p<0.0001. (B) Quantitative RT-PCR was performed to analyze NIK mRNA expression in BT25 
and BT114 glioma cells. Graph shows fold change NIK expression relative to BT25 cells, averaged 
from triplicate wells from one representative experiment. Unpaired test P-values:*p=0.0351. (C) NIK 
protein expression in BT25 and BT114 cells was compared using flow cytometry with antibodies 
directed to NIK (Abcam, 7204) or isotype controls. (D) Quantitative RT-PCR was performed to analyze 
expression of MT1-MMP in BT25 and BT114 cells. Graph shows fold- change MT1-MMP expression 
relative to BT114 cells, averaged from triplicate wells from one representative experiment. Student’s 
t-test P-value ****p<0.0001. (E) MT1-MMP activity was assayed using the Sensolyte 520-MMP-14 
Assay kit (AnaSpec) with extracts made from the indicated cells after 8 hours of invasion and 
incubation with TIMP-1 conditioned media. Graph from one representative experiment (n=3) is 
depicted, showing average RFU (relative fluorescence units) from three replicates per cell type. 
Unpaired Student’s t-test P-value **p=0.0031. (F) Gelatin zymogram was performed to evaluate matrix 
degradation by BT25 and BT114 cells. 
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Figure 9. NIK increases MT1-MMP phosphorylation, but not mRNA expression.  
(A) Representative western blot analysis (n=4) of BT114-Control, -NIK(WT) or -NIK(S867A) cells. 
Whole cell lysates were probed with indicated antibodies. (B) qPCR analysis was performed to analyze 
expression of MT1-MMP and NIK in BT114 cells expressing Control, NIK(WT) or NIK(S867A). 
Graph shows fold-change MT1-MMP and NIK expression relative to BT114-Control cells. Average 
gene expression was calculated from triplicate wells from a representative experiment that was repeated 
three times. GAPDH expression was used as endogenous control. Statistical analysis of gene expression 
data was calculated using 2-way ANOVA with Tukey’s HSD post test. Different letters indicate 
statistically significant differences with multiplicity adjusted P-values < 0.0001 for all comparisons. 
(C) Quantitative RT-PCR analysis was performed to analyze expression of MT1-MMP and NIK in 
BT114-Control and BT114-sgNIK cell untreated or treated with TWEAK (10ng/ml) for 24 hours. 
Graph shows fold-change MT1-MMP and NIK expression relative to untreated BT114-Control cells 
from triplicate wells from one representative experiment that was repeated three times. RPLP0 
expression was used as endogenous control. Statistical analysis of gene expression data was calculated 
using 2-way ANOVA with Tukey’s HSD post test. Different letters indicate statistically significant 
differences with multiplicity adjusted P-values: a vs. b and b vs. c < 0.0001; a vs. c = 0.0004. 

































Figure 10. NIK increases MT1-MMP pseudopodial localization.  
(A) BT114 cells expressing Control, NIK(WT) or NIK(S867A) grown on collagen-coated coverslips 
were stained with DAPI (blue), Alexa Fluor 488-phalloidin (green), and anti-pMT1-MMP (Y573) 
(red). Confocal microscopy was used to evaluate subcellular localization of pMT1-MMP. Images of 
representative cells from one of six experiments are shown. Arrows indicate pMT1-MMP localized to 
pseudopodia. (B) Quantification of pMT1-MMP staining that localized to pseudopodia was performed 
using images from obtained in (A) and normalized to total cellular pMT1-MMP staining: at least 30 
cells from six different experiments were used for quantification. One-way ANOVA with Tukey’s HSD 
post test multiplicity adjusted P-values: * 0.0394 Control vs. NIK(WT); *** 0.0009 Control vs. 
NIK(S867A). (C) Immunofluorescence staining of BT114 cells expressing Control, NIK(WT) or 
NIK(S867A) grown on collagen-coated coverslips was performed to demonstrate colocalization 
between pMT1-MMP and cortactin at pseudopodial structures. Cells were stained with DAPI (blue), 
pMT1-MMP (green), and cortactin (red), and imaged using confocal microscopy. Volumetric views of 
confocal Z-stacks were made using Nikon NIS Elements software and rotated to show 3D view of 
pseudopodia.  (D) MT1-MMP activity was assayed in the indicated cells after 16 hours of invasion 
using the Sensolyte 520-MMP-14 Assay kit (AnaSpec) with modifications to specifically quantify 
MT1-MMP activity. Representative graph from three experiments depicts average RFU (relative 
fluorescence units) ± SD. One-way ANOVA with Holm-Sidak post test multiplicity adjusted P-values: 
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To test the hypothesis that NIK enhances MT1-MMP activity post-
transcriptionally, we used a heterologous assay involving ectopic co-expression of 
NIK(S867A) and MT1-MMP in HEK293FT cells. Control HEK293FT cells (vector only) 
lack MT1-MMP, exhibit low MT1-MMP activity and do not invade collagen (Figure 12A, 
B, D, E). Ectopic expression of NIK(S867A) alone in HEK293FT cells does not increase 
endogenous MT1-MMP protein, mRNA or enzymatic activity (Figure 12A, B, C), and 
does not enhance the invasive potential of these cells (Figure 12D, E). While ectopic 
expression of a CMV-driven MT1-MMP promotes HEK293FT cell invasion as previously 
reported (138), co-expression of NIK and CMV-MT1-MMP significantly increased 
HEK293FT cell invasion (see side-view images of collagen matrices and quantification of 
invasion cell densities; Figure 12D, E). Consistent with increased cell invasion, we 
observed that HEK293FT cells co-expressing NIK and MT1-MMP have increased MT1-
MMP enzymatic activity compared with expression of MT1-MMP alone (Figure 12B).  
These data demonstrate that NIK can enhance MT1-MMP enzymatic activity and 
localization within pseudopodia without increasing MT1-MMP expression. 
















Figure 11. Loss of NIK decreases invasion and results in loss of pseudopodial pMT1-MMP 
localization.  
(A) qPCR analysis of NIK and MT1-MMP mRNA expression in BT25-Control and BT25-sgNIK cells 
that were untreated or treated with TWEAK for 24 hours. Graph shows data from triplicate wells from 
one representative experiment that was repeated three times. GAPDH expression was used as 
endogenous control. Statistical analysis of gene expression data was calculated using 2-way ANOVA 
with Tukey’s HSD post test. Different letters indicate statistically significant differences with the 
following multiplicity adjusted P-values: p<0.0001 for “a vs. b”; p=.001 for “a vs. c”. (B) 
Representative western blot analysis of pMT1-MMP (Y573) and MT1-MMP expression in BT25-
Control and BT25-sgNIK cells. Whole cell lysates were probed with the indicated antibodies. (C) 
BT25-Control and BT25-sgNIK cells grown on collagen-coated coverslips were stained with DAPI 
(blue), Alexa Fluor 488-phalloidin (green), and anti-pMT1-MMP (Y573) (red). Confocal microscopy 
was used to evaluate subcellular localization of pMT1-MMP. Images of representative cells from one 
of three experiments are shown. Arrows indicate pMT1-MMP localized to pseudopodia. Scale bar = 
10 μm. (D) Quantification of pMT1-MMP staining that localized to pseudopodia was performed using 
images obtained in (C) and normalized to total cellular pMT1-MMP staining:  BT25-Control (n= 30 
cells) and BT25-sgNIK (n=30 cells). Cells from three different experiments were used for 
quantification. Unpaired Student’s test P-value ****p<0.0001. 
 
 

































Figure 12. NIK increases MT1-MMP activity and invasion in a heterologous HEK293FT system. 
HEK293FT cells were transfected to express LacZ and Luciferase, LacZ and NIK(S867A), LacZ and 
MT1-MMP, or NIK(S867A) and MT1-MMP. (A) Whole cell lysates were probed with antibodies 
directed against NIK, RelB, MT1-MMP and Actin using western blotting. (B) MT1-MMP activity assays 
were performed as described in Figure 3E, using lysates made from HEK293FT cells after 24 hours of 
invasion. RFU= relative fluorescence units. One-way ANOVA with Tukey’s HSD post test was used for 
statistical analysis. Different letters indicate statistical significance. Multiplicity adjusted P-value <0.0001 
for all comparisons. (C) Quantitative RT-PCR was performed to analyze MT1-MMP mRNA expression 
in 293FT cells transfected to express luciferase (Control) or NIK(S867A). Graph shows fold change MT1-
MMP expression relative to 293FT cells expressing Luciferase (Control), averaged from triplicate wells 
from one representative experiment. Unpaired Student’s t-test P-values = 0.6453 (ns). (D) Quantification 
of average number of invading cells per field ± SD. At least 4 wells were quantified per cell type for three 
independent experiments. A representative graph is shown. Significance was calculated using one-way 
ANOVA with Tukey’s HSD test and letters indicate statistically significant differences. Multiplicity 
adjusted P-values: p <0.0001 for all comparisons. (E) Invasion assays were fixed with 4% 
paraformaldehyde, stained with Alexa Fluor 488-phalloidin (green) and DAPI (blue) and imaged using 
confocal microscopy. Z-stacks were compressed and rotated to demonstrate side-view of invasion.  
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TWEAK and NIK promote invasion and increase pseudopodial pMT1-MMP localization 
independently of the canonical NF-B pathway 
NIK is required for activation of noncanonical NF-B transcription factors, but 
can also regulate canonical NF-B proteins (p65- and cRel)  (26, 139, 140). Since 
RelA/p65 was previously reported to regulate expression of MT1-MMP (124, 125), we 
sought to determine whether TWEAK- or NIK- induced invasion and regulation of pMT1-
MMP required canonical NF-B signaling. We first noted that neither NIK(WT) or 
NIK(S867A) affected p65 phosphorylation (pS536), a marker of p65 transcriptional 
activation (141) (see Figure 9A). Moreover, neither TWEAK treatment nor NIK 
expression significantly affected p65 nuclear translocation(30) (Figure 13), suggesting 





















Figure 12. Continued. 









































Figure 13. NIK expression or TWEAK treatment does not induce canonical NF-κB.  
BT114 cells expressing Vector (Control) or NIK(S867A) seeded onto collagen- coated coverslips were 
treated with nothing (Control), 10 ng/ml TWEAK for 4 hours or 20 ng/ml TNFα for 30 minutes, as a 
control to demonstrate p65 movement to nucleus, before fixing with 4% paraformaldehyde. (A) 
Coverslips were immunostained with antisera directed to p65 (green), stained with DAPI (blue) to 
visualize nuclei, and imaged using confocal microscopy. Arrowheads indicate p65-negative nuclei. 
Arrows indicate p65-positive nuclei. Scale bars = 10 μm. (B) 50 cells per treatment per experiment 
(n=3) were examined for the percentage of p65 localization to the nucleus (Nuc) or cytoplasm (Cyto). 
A representative experiment is shown.  
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To test the effects of TWEAK and NIK on invasion in the absence of specific NF-
B proteins (Figure 14A-C), we exploited the ability of mouse embryonic fibroblasts 
(MEFs) to invade collagen in an MMP-dependent manner (Figure 14D). MEFs derived 
from homozygous p65-/- or p65-/-;cRel-/- mice showed significantly reduced invasion 
compared to their corresponding pooled wild-type MEFs, while RelB-/-MEFs invasion was 
almost completely abrogated (Figure 14E). TWEAK treatment significantly enhanced 
invasion in all MEFs, with the exception of RelB-/-  MEFs (Figure 14E, F). Notably, 
TWEAK-enhanced invasion of p65-/- MEFs was accompanied by a significant increase of 
pMT1-MMP located within pseudopodia (Figure 15A, B).  
We explored the invasion potential of NIK-/- MEFs and their corresponding NIK+/+ 
wild-type controls (142). In contrast to the wild-type control MEFs of NF-B mutant 
strains (see above), NIK+/+ MEFs were only minimally invasive in 3-D collagen matrices, 
as were NIK-/- MEFs (Figure 15C). We speculate that the variability in WT MEF invasion 
may be due to different genetic backgrounds of mice from which the MEFs were isolated. 
Regardless, the NIK+/+ MEFs exhibited robust TWEAK-induced invasion, which was 
significantly impaired in NIK-/- MEFs (Figure 15C). Moreover, we also observed 
decreased pseudopodial localization of pMT1-MMP in NIK-/- MEFs compared with 






















Figure 14. MEF invasion is MMP dependent and MT1-MMP expression and localization to 
pseudopodia increases with TWEAK treatment.  
(A) Western blot analysis confirms loss of p65 in null MEFs ± TWEAK treatment (10ng/ml for 24 
hours) using indicated antibodies. (B) WT and p65-/-; cRel-/-
 
MEFs were treated with 10 ng/ml TWEAK 
for indicated times. Western blot analysis confirms loss of NF-􏰃B proteins, p65 and cRel in null MEFs, 
using indicated antibodies (cRel: Cell Signaling Technology, CST4727). (C) Western blot analysis 
confirms loss of RelB in null MEFs, using indicated antibodies. (D) Average invasion density 
quantification ± SD using WT MEFs treated with vehicle control (DMSO) or the MMP inhibitor TAPI-
2 (2.5 or 5 μM) before seeding onto 3D collagen matrices. Four wells were quantified per experiment 
for three independent experiments. Statistical significance was calculated with one way ANOVA with 
Dunnett’s multiple comparisons test where ****p<0.0001 for 2.5 and 5 μM TAPI-2 vs. DMSO. (E) 
WT mouse embryonic fibroblasts (MEFs) and NF-B null MEFs were allowed to invade collagen 
matrices ± 10 ng/ml TWEAK. WT represents pooled invasion data from p65+/+, p65/cRel+/+ and 
RelB+/+ MEFs (± TWEAK). Three independent experiments were performed counting three invading 
wells per treatment. Differences between untreated and TWEAK treated samples of a given genotype, 
as well as differences among untreated or TWEAK treated cells of different genotypes were analyzed 
using 2-way ANOVA with Tukey’s HSD post test. Statistically significant differences are indicated by 
different letters. Multiplicity adjusted P-values: ****<0.0001 between all letters, except ***<.001 for 
“c vs. e” and *<0.01 for “c vs. f.”  (F) Untreated or TWEAK-treated WT MEFs were seeded onto 
collagen matrices and allowed to invade 24 hours. Side view images of invasion are shown. Scale bar 
= 50 μm.  
 
 
























Figure 15. Loss of NIK in MEFs abrogates surface localization of pMT1-MMP in response to 
TWEAK.  
(A) p65-/- MEFs were seeded onto collagen coated coverslips and treated with or without (Untreated) 
10 ng/ml TWEAK for 4 hours. Cells were fixed and stained with anti-pMT1-MMP (red), Alexa Fluor 
488-phalloidin (green), and DAPI (blue), and imaged using confocal microscopy. Scale bar = 10 μm. 
Right panels show the zoomed portion of the boxed image on the left. Images of representative cells 
from one of three experiments are shown. (B) Blinded quantification of pMT1-MMP intensity beyond 
actin-rich protrusions expressed in arbitrary units (AU) ± SEM of images of p65-/- MEFs ± TWEAK 
(10ng/ml). At least 30 cells per treatment from three independent experiments were used for 
quantifications. **p<0.01 using unpaired Student’s t-test. (C) Invasion density of WT NIK-/- MEFs, 
untreated or treated with TWEAK (10 ng/ml) and allowed to invade 3D collagen matrices for 48 hours. 
Three wells were quantified per treatment in three independent experiments. Graph depicts one 
representative experiment. Statistical analysis of invasion data was calculated using 2-way ANOVA. 
Different letters indicate statistically significant differences with multiplicity adjusted P- value of 
p<0.0001 for all comparisons. (D) WT and NIK-/-MEFs were seeded onto collagen coated coverslips, 
and treated and stained with anti-pMT1-MMP antibody (red), Alexa Fluor 488-phalloidin (green), and 
DAPI (blue), and imaged using confocal microscopy. Scale bar = 10 μm. (E) Intensity of pMT1-MMP 
staining beyond actin-rich protrusions expressed in arbitrary units (AU) ± SEM of images from Figure 
15D of WT and NIK-/- MEFs untreated or treated with 10ng/ml TWEAK. Statistical significance was 
calculated using 2-way ANOVA with Tukey’s HSD post test. Statistically significant differences are 
indicated by different letters. Multiplicity adjusted P-values: <0.0001 for “a vs. b.” (F) WT and NIK-/- 
MEFs were treated with or without MG132 (5 μM) for 1 hour to prevent NIK degradation and then 
untreated, or treated with TWEAK (10 ng/ml), as indicated for 5 hours. Western blot analysis using 
indicated antibodies confirms loss of NIK protein in NIK-/- MEFs.  
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Next, we tested whether NIK is sufficient to promote MEF invasion in the absence 
of canonical NF-B proteins. Expression of NIK(WT) in p65-/-;cRel-/- MEFs increased 
invasion (Figure 16A) and pseudopodial localization of pMT1-MMP (Figure 16B). 
Moreover, expression of NIK(WT) did not significantly alter expression of MT1-MMP 

































Figure 15. Continued. 
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results demonstrate that TWEAK and NIK promote invasion and pMT1-MMP 


































Figure 16. TWEAK increases invasion and pMT1-MMP pseudopodia localization in the absence 
of canonical NF-B p65/cRel proteins.  
(A) Invasion density of p65-/-;cRel-/- knockout MEFs transduced to express vector (Control) or 
NIK(WT). At least four wells were quantified per treatment for three independent experiments. Graph 
depicts one representative experiment. Unpaired t-test P-value: *0.01.  Panel shows western blot 
analysis of p65-/-;cRel-/- knockout MEFs expressing vector (Control) or NIK(WT) confirming 
exogenous NIK expression. (B) p65-/-;cRel-/-MEFs were seeded onto collagen coated coverslips, and 
treated and immunostained as described in Figure 15A. Scale bar = 10 μm. (C) Quantitative RT-PCR 
was performed to analyze MT1-MMP expression in p65-/-;cRel-/- MEFs expressing vector alone 
(Control) or NIK. GAPDH expression was used as endogenous control. Gene expression data was 
averaged from triplicate wells from one representative experiment of three total experiments. Unpaired 
Student’s t-test P-values = 0.0654 (ns).   
 
  49 
NIK expression is associated with increased pMT1-MMP in orthotopic xenograft tumors 
We previously demonstrated that BT114-NIK cells formed larger tumors in vivo, 
compared with BT114-Control cells (30). We used tumor tissue from these animals for 
immunohistochemical analyses. Immunofluorescence staining verified increased NIK 












Figure 17. NIK increases tumor growth and pMT1-MMP in vivo.  
(A) Tumor sections derived from BT114-Control (n=3) or BT114-NIK (n=3) xenograft tumors were 
stained with DAPI (blue) and anti-NIK (green), and imaged using confocal microscopy. Scale 
bars=20μm (panels a, d) and 50μm (panels b, e). Red outlined boxes are in panels b and e are magnified 
in panels c and f, respectively. (B) Graph shows percent NIK expression in tumors quantified from five 
sections of each tumor using Image J software analysis. **p=0.0011 vs. BT114-Control using unpaired 
Student’s t-test.  (C, D) Immunohistochemical diaminobenzidine (DAB) staining (brown) of sections 
from BT114-Control (C) or BT114-NIK (D) tumors with anti-pMT1-MMP (Y573) antibody. The 
portion of the image marked with a red dotted square is shown as a zoomed image on the right. Sections 
from non-injected brain region are shown as a negative control. Scale bar = 50 μm.  (E) Graph shows 
quantification of pMT1-MMP staining (Figure 17C-D) from 5 sections of tumors derived from BT114-
Control or BT114-NIK cells using IHC profiler (143) to measure positive pixel counts for DAB 
staining; ± SEM **p=0.0014 vs. BT114-Control using unpaired Student’s t-test.  
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Adjacent tumor sections were used for immunohistochemical staining, which 
revealed increased expression of pMT1-MMP in BT114-NIK tumors, compared to 
BT114-Control tumors (Figure 17C-E). As a control, we examined pMT1-MMP staining 
in sections from the non-injected brain hemisphere without tumor growth (Figure 17C, D; 
bottom panels) (143). These data demonstrate that increased NIK expression in tumors 















Figure 17. Continued. 
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NIK and MT1-MMP expression in human glioma correlates with poor survival 
To investigate the significance of NIK and MT1-MMP in human tumors, we 
examined their expression ex-vivo in human glioma tissue. Results from these 
experiments revealed co-expression of NIK and pMT1-MMP in three patient-derived 
tumor samples (Figure 18A).  To determine whether the observed co-expression of NIK 
and MT1-MMP is relevant for disease pathogenesis, we analyzed NIK and MT1-MMP 
expression in TCGA datasets through the cBioPortal Cancer Genome for Cancer 
Genomics (131, 132). Kaplan-Meier plots reveal that increased NIK and MT1-MMP 
mRNA expression correlates with poor survival of glioblastoma (GBM) patients (Figure 
18B, C). The mean survival of GBM patients with increased NIK and MT1-MMP 
expression (5% of cases) is 10.6 months compared with 14.1 months for patients with 
unaltered expression (Figure 18C). In lower grade glioma (LGG), the correlation between 
high NIK and MT1-MMP expression (12% of cases) and poor patient survival was even 
higher (Figure 18D), suggesting that high NIK and MT1-MMP expression is a prognostic 
indicator for LGGs that are likely to progress to more aggressive tumors. Furthermore, the 
time to disease progression for LGG patients with high NIK and MT1-MMP expression 
is significantly shorter and is reflected by a higher rate of relapse (Figure 18E). 
Collectively, these results demonstrate a strong correlation between NIK and MT1-MMP 








































Figure 18. NIK and MT1-MMP are co-expressed in human glioma and correlate with poor 
patient survival.  
(A) Sections of human glioma ex-vivo biopsy tissue were stained with antibodies specific for pMT1-
MMP (Y573) (red) and NIK (pre-conjugated with AF488; green). Representative images are shown 
from three tumors. (B) Kaplan-Meier curve representing TCGA patient survival data from glioblastoma 
(GBM) patients with upregulated NIK (MAP3K14) and MT1-MMP (MMP14) mRNA expression. 
Data was downloaded from cBioPortal for Cancer Genomics TGCA, Cell 2013 dataset (10). Log-rank 
Mantel-Cox test indicates statistical significance with p=0.0459. (C) Mean survival (months) of GBM 
patients with unaltered (n=509) or upregulated NIK and MT1-MMP expression (n=27). Unpaired 
Welch t-test indicates statistical significance with ** p=0.0038. (D) Kaplan-Meier curve representing 
TCGA patient survival data from lower grade glioma (LGG) patients with upregulated NIK and MT1-
MMP mRNA expression (LGG Provisional raw data at the NCI). Log-rank Mantel-Cox test indicates 
statistical significance with p=5.42e-5.  (E) Kaplan Meier curve representing disease-free time for LGG 
patients with upregulated NIK and MT1-MMP. Log-rank Mantel-Cox test indicates statistical 
significance with p=0.0202. 
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DISCUSSION 
Aberrant activation of NIK has been shown to have oncogenic roles in several 
cancers, including melanoma, ovarian cancer, and multiple myeloma (27, 144, 145), 
primarily through regulation of proliferation and cell survival (139, 145, 146). However, 
the role of NIK in CNS tumor pathogenesis, and particularly in tumor cell invasion, has 
not been clearly established. Here, we demonstrate that NIK plays a critical role in 
regulating MT1-MMP phosphorylation, pseudopodial localization and enzymatic activity 
to drive cell invasion. Our data suggest that NIK regulates MT1-MMP activity through a 
mechanism that is both post-transcriptional and indirect. A post-transcriptional process is 
indicated since we observed that NIK increases MT1-MMP phosphorylation and activity, 
but does not affect MT1-MMP mRNA expression (Figures 9B, 11A). Since 
phosphorylation of Y573 is the critical step in enhancing movement of MT1-MMP to the 








Figure 18. Continued. 
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MT1-MMP phosphorylation is indirect. However, we cannot rule out the possibility that 
NIK phosphorylates MT1-MMP at either the T567(147) or S577 residues within the 
cytoplasmic tail, which may, in turn, regulate Y573 phosphorylation. Alternatively, NIK 
may regulate MT1-MMP at the step of furin cleavage19, 20. Collectively, this study is the 
first to demonstrate that NIK expression promotes tumor cell invasion by regulating MT1-
MMP at the post-transcriptional level.  
We demonstrate a strong correlation between cell invasion and expression of NIK 
at the protein and mRNA levels (Figures 1, 2). This correlation is consistent with analyses 
of both low and high grade glioma databases, indicating that increased expression of NIK 
and MT1-MMP is associated with poor patient survival (Figure 18).  Therefore, high NIK 
and MT1-MMP co-expression may be key prognostic indicators, not only for high-grade 
gliomas, but also for lower grade gliomas that are likely to progress to more aggressive, 
therapy-resistant tumors. In support of this hypothesis, NIK was recently identified in an 
analysis of protein interaction networks associated with glioma chemoresistance (148).  
Our study is the first to link expression of NIK to pro-invasive cell shape 
phenotypes (Figure 6, 7), which play a central role in driving cancer cell dissemination 
through healthy tissue (91). NIK expression significantly enhances pMT1-MMP 
localization within pseudopodia, to promote increased invasion of 3D matrices (Figures 
10, 11, 15, 16). The expansion of pseudopodia length in 2D coupled with increased 
invasion responses in 3D matrices suggest that NIK may enhance or stimulate the 
transition from invadopodia to pseudopodia (149, 150), which is critical for cell invasion 
(91).  Interestingly, differences in cell shape were recently shown to influence the extent 
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of canonical NF-B activation (151). Although NIK does not require RelA/p65 to promote 
cell invasion and localization of pMT1-MMP to pseudopodia (Figure 15, 16), NIK may 
be part of a feedback mechanism that tunes the levels of canonical NF-B activation 
through regulation of cell shape.  
Current therapeutic strategies for targeting NF-B signaling in high-grade glioma, 
as well as other tumors, focus on inhibition of the canonical/p65-mediated pathway (152), 
which has well-established tumor-promoting functions (153, 154). Here, we have 
established new roles for NIK in regulating MT1-MMP activity and tumor cell invasion 
that are independent of RelA/p65, underscoring the importance of developing treatment 
strategies that target both the canonical and noncanonical NF-B pathways. Indeed, since 
invadopodia and pseudopodia formation drive dissemination and metastasis of several 
cancers (91), inhibition of NIK may be an efficacious therapeutic approach in many 
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CHAPTER III  
NIK CONTROLS GLIOMA CELL ADHESION AND INVASION THROUGH 
REGULATION OF LEADER CELL MARKER, ITGA11 
SUMMARY 
A hallmark of high grade glioma is highly aggressive, diffuse invasion into normal 
brain tissue, contributing to a 100% recurrence rate and resistance to current therapies. 
Recent efforts to determine molecular differences in high grade glioma and define tumor 
subtypes have revealed that the noncanonical NF-B transcription factor RelB is 
upregulated in the highly aggressive mesenchymal subtype, as well as in recurrent tumors. 
We have found noncanonical NF-B signaling drives directed glioma cell invasion into 
3D collagen matrices. Stabilization of NF-B-inducing kinase (NIK), a critical driver of 
noncanonical NF-B signaling, promoted glioma cell adhesion, spreading, and 
pseudopodia formation on collagen substrates. While normal brain tissue expresses low 
levels of collagen, collagen type I is upregulated within the stroma and surrounding tissue 
of glioma. As NIK expression appeared to regulate glioma cell behavior on collagen, we 
investigated whether NIK controls the expression of collagen-binding and other integrins. 
We found NIK expression upregulated the integrin alpha 11 subunit (ITGA11), while it 
did not significantly affect the expression of ITGA1, ITGA2, or ITGA10. Analysis of 
human tumor samples revealed that ITGA11 expression was increased in glioma tissue 
compared to normal brain tissue. Furthermore, when testing multiple glioma lines, 
ITGA11 expression positively correlated with invasiveness into 3D collagen matrices. In 
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a heterologous system, ITGA11 and MT1-MMP, a key matrix metalloproteinase, formed 
a complex, suggesting these transmembrane proteins could interact in glioma cells to 
facilitate coordinated recognition and degradation of collagen during invasion. Silencing 
of ITGA11 in an invasive glioma line attenuated invasion into 3D collagen matrices.  NIK 
expressing cells were capable of enhancing the invasiveness of normally non-invasive 
glioma cells. Collectively, these data reveal an ability of NIK to promote collective glioma 
cell invasion, pseudopodia formation, and ITGA11 expression. These data suggest 
ITGA11 could serve as a novel marker for more invasive glioma and a potential 
therapeutic target in glioma.  
 
INTRODUCTION 
High grade gliomas are uniformly fatal. These devastating tumors are the most 
common primary brain tumor and have a median survival time of approximately one year 
(2). A hallmark of these tumors is aggressive, diffuse invasion into normal brain tissue. 
Though surgical resection can remove the majority of the tumor, a balance between 
removal of the tumor while maintaining neurological function leads to incomplete 
excision of the tumor. While adjuvant chemotherapy and radiation have improved survival 
time (155), the tumors retain a 100% recurrence rate due to survival and regrowth of the 
cells that invaded past the margins of resection. Therefore, understanding the mechanisms 
controlling the invasiveness of these tumors is of fundamental importance to the 
development of therapeutics to combat this disease. 
  58 
Genetic profiling of high grade glioma has defined distinct subtypes based on 
molecular and clinical signatures (11, 156). In particular, tumors of the mesenchymal 
subtype are characterized as more aggressive and endothelial-like, expressing markers of 
angiogenesis. Patients with the mesenchymal subtype have shorter survival time, relative 
to other subtypes. Further, regardless of the original subtype, most glioma tumors recur as 
the mesenchymal subtype (156). Separate studies found the noncanonical NF-B 
transcription factor RelB was upregulated in mesenchymal tumors (11), and the recurrent 
tumors often had increased RelB copy number (112). Noncanonical NF-B signaling is 
driven by the stabilization of NF-B inducing kinase (NIK or MAP3K14) in response to 
specific cytokines, such as TWEAK, leading to downstream translocation of RelB to the 
nucleus where it can act on target genes (17-19, 30). Our previous work demonstrated that 
RelB expression positively correlated with mesenchymal glioma tumor invasiveness into 
3D type I collagen matrices and RelB silencing attenuated glioma invasiveness and tumor 
growth (29, 30).  
Consistent with RelB, stabilization of NIK also stimulates glioma cell invasion 
(30, 157). Furthermore, Chapter II found that NIK regulates the phosphorylation and 
activity of the type I collagen matrix metalloproteinase, MT1-MMP (or MMP14) and the 
localization of MT1-MMP to pseudopodial structures. NIK also controlled glioma cell 
spreading and pseudopodia formation on collagen in 2D. In human patients, upregulation 
of NIK and MT1-MMP is negatively correlated with survival time (157). However, the 
manner through which noncanonical NF-B signaling drives glioma cell growth and 
invasion is largely unknown. 
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The extracellular matrix (ECM) composition of normal brain differs substantially 
from glioma. While type I collagen is the most highly expressed protein in the body, the 
normal brain expresses very little collagen, making it a very soft tissue. However, the 
ECM of glioma is composed of collagen, hyaluronan, tenascin-C, and vitronectin (107, 
158, 159). Expression of type I collagen within the tumor stroma has been shown to 
positively correlate with increasing grade of glioma; grade IV glioblastoma multiforme 
tumors express the highest levels of type I collagen (107). The presence of collagen within 
the tumor microenvironment can provide adhesive scaffolding for migrating cells, release 
growth factors to promote invasion and proliferation, and induce the activation of pro-
invasive signaling after recognition by collagen binding receptors (160, 161). Thus, the 
increased expression of collagen in glioma likely contributes to aggressive behavior in 
glioma, although a specific mechanism has not been identified. 
Integrins are transmembrane receptors for ECM and basement membrane proteins 
that consist of heterodimers of alpha and beta subunits. Currently there are 18 alpha and 8 
beta subunits, which can form 24 integrin pairs, providing substrate specificity (162). 
Once integrins adhere to an ECM protein, the intracellular tails will unfold to reveal a 
binding site for the actin binding protein, talin. Therefore, integrins couple the 
extracellular environment and the actin cytoskeleton (163). Integrin attachment to the 
ECM forms a nascent adhesion which will develop into a focal adhesion, containing 
hundreds of proteins, including F-actin, and the actin binding proteins, talin, paxillin, 
vinculin, and alpha-actinin. Several signaling molecules are activated during focal 
adhesion assembly, including FAK, Src, and members of the small Rho GTPase family, 
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Rac1 and Cdc42. Downstream actin remodeling events stimulate the production of actin-
rich invasive structures. Pseudopodia develop from sites of integrin-matrix adhesion and 
localize proteases that degrade the ECM (164-167). In particular, MT1-MMP has been 
found to be recruited to integrin adhesive sites and initiate collagen degradation, and 
promote invasion (79, 81, 82, 113, 114, 168, 169). 
Integrins have been shown to be upregulated in many solid tumors and are thought 
to stimulate tumor cell migration (170). In glioma, the v3 and v5 integrins display 
increased expression at the border between the tumor and normal brain tissue and may 
contribute to glioma cell invasion (171). Expression of the integrin subunits that form 
collagen-binding integrins has not been studied in glioma, however. There are four alpha 
integrin subunits, ITGA1, ITGA2, ITGA10, and ITGA11, which heterodimerize with 
ITGB1 to bind type I collagen, recognizing the GFOGER motif within fibrillar collagen 
(35, 172). Notably, an association between ITGA11 expression and tumor cell invasion 
and progression has been recently investigated. Increased ITGA11 expression was found 
in the subset cells that initiate collective cell invasion in breast cancer lines and its 
expression correlates with progression of non-small cell lung cancer (41, 44). A role for 
ITGA11 in mediating glioma cell invasion has not been determined. In this study, we 
demonstrate noncanonical NF-B signaling regulates the expression of ITGA11 to control 
invasion of high grade glioma.  
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MATERIALS AND METHODS 
Reagents 
Collagen was isolated and prepared as previously described (127).  Osteopontin 




BT25 and BT114 cell lines were obtained from human glioma patients and 
described previously (128). U87 glioma cells were purchased from ATCC. Glioma lines 
were maintained in Neural Stem Cell (NSC) medium (DMEM/F12, 1x B-27 Supplement 
minus Vitamin A, 1x Glutamax, 50 ng/ml EGF, 50 ng/ml bFGF, 1x Pen/Strep). 
HEK293FT cells were purchased from Invitrogen (Grand Island, NY) and were cultured 
in DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen).  All cells were 
incubated at 37°C with 5% CO2. Osteosarcoma and melanoma cells were a kind gift of 
Carl Gregory (174) and Alan Tackett, respectively, and both cell lines were grown in 
DMEM supplemented with 10% FBS.  
 
Constructs 
pLenti6 overexpression constructs for NIK were previously described (157). 
Briefly, NIK cDNA was subcloning cDNA into pLenti6-V5-DEST (Addgene, Cambridge, 
MA) using the GATEWAY™ Cloning System. Luciferase (Promega, Madison, WI) 
coding sequences were subcloned into pLenti6-V5-DEST and used as controls for NIK 
  62 
overexpression. NIK(S867A) mutation was obtained by PCR cloning using oligo primers 
containing the mutation. NIK gene–knockout cells (BT25-sgNIK) were described 
previously (157). MT1-MMP-His cloning has been previously described (175). The 
enhanced GFP construct has been detailed previously (176). ITGA11 expression 
constructs were amplified from human umbilical vein endothelial cell cDNA using 
primers (5’-ACTGGTCGACGCCACCATGGACCTGCCCAGGGG-3') and (5’-
ACTGGGTACCCTCCAGCACTTTGGGGGTGG-3') and inserted into the pFlag-CMV2 
vector (Sigma) to generate a C-terminal Flag tag on ITGA11. Positive clones were tested 
for expression by transfection into HEK293FT cells and fidelity by sequencing. 
 
Lentiviral production 
HEK293FT cells were transfected with 24 μg of lentiviral plasmids using 72 μg of 
polyethyleneimine (Polysciences Inc., Warrington, PA). Lentiviruses were harvested after 
three days and used to infect 2x105 BT114 or U87 cells. Transduced BT114 and U87 cells 
were selected for 14 days in NSC medium 6 μg/ml blasticidin or 200 ng/ml puromycin, 
respectively, (Invitrogen, San Diego, CA) to verify stable transduction. 
 
Invasion assays 
Invasion assays were established as previously described (127). Briefly, 3D 
collagen type I matrices were prepared at a final concentration of 2 mg/ml. Before 
polymerization, 28 μl of collagen matrix was added to each well of a half-area 96-well 
plate and allowed to polymerize for 45 minutes at 37°C with 5% CO2. Following collagen 
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polymerization, dissociated cells (40,000 cells/100 μl DMEM) were seeded and allowed 
to incubate at 37°C with 5% CO2. Invasion assays were fixed after 48 hours incubation, 
with 3% glutaraldehyde in PBS and stained with 0.1% toluidine blue in 30% methanol.  
Co-culture invasion assays were established as described above. BT25-Control and BT25-
sgNIK cells were labeled with 1 μg/ml DiO or DiI (Thermo Fisher, V22886, V22885) by 
incubating for 20 minutes and washing per manufacturer’s instructions. Labeled cells were 
seeded individually in separate wells at 40,000 cells/100 μl DMEM or combined at 20,000 
cells of each type/ 50 μl DMEM per cell type. Unlabeled cells were also seeded in separate 
wells at 40,000 cells/100 μl DMEM, as a control. Cells were fixed after 48 hours in 4% 
paraformaldehyde for 30 minutes, and rinsed with Tris-Glycine buffer, containing 0.3% 
Tris and 1.5% glycine, and stained with 1 μM DAPI (Molecular Probes) for 30 minutes. 
Collagen gels were cut, mounted, and imaged from the side using a Nikon TI A1R inverted 
confocal microscope to capture Z-stacked images with a 0.5 μm step size. 
 
Quantification of invasion responses 
Invasion density was quantified manually in toluidine blue stained invasion assays 
as the average number of structures invading past the monolayer, per field, using an 
eyepiece fit with a 10x10 ocular grid. At least four wells per treatment group were counted, 
per experiment, for three independent experiments. To visualize invasion responses, after 
fixation and staining, collagen gels were removed from the well, cut and imaged from the 
side using an Olympus CKX41 microscope with a Q-Color 3 camera at 10x magnification. 
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Adhesion assays 
High binding EIA/RIA 96-well plates were coated with 1.25µg/ml of collagen type 
I, fibronectin, or osteopontin and allowed to coat overnight at 4C with gentle mixing. The 
matrix proteins were removed and the wells were blocked with 10 mg/ml BSA for 1 hour. 
Negative controls consisted of blank wells blocked with BSA alone.  BT114, BT25, or 
U87 cells were seeded in triplicate at 40,000 cells per well and allowed to attach for 30 
minutes at 37C. Unattached cells were washed before fixing in 3% formalin and staining 
with 0.1% amido black in 10% acetic acid and 30% methanol. Stained wells were rinsed 
with water and dried before adding 50 μl 2N NaOH. Absorbances at 595 nm were read 
using a Victor X3 Multilabel Reader (PerkinElmer).  
 
RNA isolation, cDNA synthesis and quantitative RT-PCR 
Cells were lysed in 700 μl RLT buffer (Qiagen, Valencia, CA) with 7μl 2-
mercaptoethanol (Sigma). Total RNA was isolated using the Qiagen RNeasy mini kit, 
according to manufacturer’s instructions. RNA was treated with RNase-Free DNase 
(Qiagen) to degrade DNA for 15 minutes at 22°C. RNA samples were run on a 1% 
acrylamide gel to test for RNA quality and stored at -80°C. 1 μg RNA was reverse 
transcribed into cDNA using Superscript III First-Strand Synthesis System (Invitrogen), 
following manufacturer’s instructions and cDNA samples were diluted 1:6 in DEPC 
treated water. Quantitative RT-PCR (qPCR) assays were performed using SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, CA) and 10 μM primers to amplify 
GAPDH (5’-AATGAAGGGGTCATTGATGG-3’, 5’-
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AAGGTGAAGGTCGGAGTCAA-3’), -Actin (5’-CATCACCATTGGCAATGAGC-3', 
5’-CGATCCACACGGAGTACTTG3’), ITGA1 (5’-TGGGTGCTTATTGGTTCTCC-3’, 




3’), ITGA10 (5’-GGTGAGAGCAGCAAAGAACC-3’, 5’-
TGGGACTGACTGAACCCTTC-3’), ITGA11 (5’-CCAGAAGGAGGACTCAGACG-
3’, 5’-GAAGGGATAGCTGACGTTGC-3’), ITGAV (5’-
CCCCGAGGGAAGTTACTTCG-3’, 5’-ATGGATCATCCTTGGCATAATCTC-3’), 
ITGB1 (5’-ACTGATTGGCTGGAGGAATG-3’, 5’-AACAATGCCACCAAGTTTCC-
3’), ITGB4 (5’-CATAGAGTCCCAGGATGGAG-3’, 5’-
CTGCTGTACTCGCTTTGCAG-3’). Three independent experiments were performed in 
triplicate wells. qPCR data was analyzed using StepOne Software (version 2.1). ΔΔCT 
values were normalized to GAPDH expression values for each sample, set relative to 
vector (Control), and converted to 2-ΔΔCT to compare the relative mRNA fold change 
expression between treatment groups.  
 
Western blotting 
Whole cell protein extracts were prepared by pelleting equal numbers of cells and 
lysing the cells in 1.5x boiling Laemmli sample buffer containing 2% -mercaptoethanol. 
Proteins were separated on 7% SDS-PAGE gels and transferred to Immobilon PVDF 
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membranes (EMD Millipore, Billerica, MA). Membranes were blocked with 5% 
evaporated non-fat milk in 0.1% Tween-20 in TBS and incubated with primary antibodies 
diluted in milk blocking buffer at 4°C, overnight. The following primary antibodies were 
used in this study: α-Actin (Calbiochem, CP01), MT1-MMP (Millipore, MAB3328), 
ITGA11 (Millipore, ab6031), and GAPDH (Abcam, ab8245). After washing in 0.1% 
Tween-20/TBS, membranes were incubated for 1 hour at room temperature with HRP-
conjugated antibodies (DAKO, Carpinteria, CA) directed against the appropriate species 
and diluted in 5% evaporated non-fat milk. Immobilon Western Chemiluminescent HRP 
Substrate (EMD Millipore) was used for detection of HRP with HyBlot CL 
autoradiography film (Denville Scientific, Metuchen, NJ). 
 
Transient transfection and immunoprecipitation 
HEK293FT cells were transiently transfected in solution with 1 μg DNA and 8 μl 
Lipofectamine (Invitrogen) and seeded at 1x106 cells per well in a 6-well plate coated with 
20 μg/ml collagen type I. Cells were allowed to incubate overnight at 37°C with 5% CO2. 
The next day, the plate was placed on ice and washed two times with 2 ml PBS with 
cations (0.9 mM Mg2+ and Ca2+). Cells were lysed in 1 ml cold lysis buffer containing 
0.5% NP-40 in PBS with cations, 1x protease inhibitor (Roche Diagnostics) and 25x 
HALT phosphatase inhibitor. Cells were incubated for 20 minutes on ice and scraped 
every 5 minutes to aid the lysis. Lysates were collected and centrifuged at 16,000xg for 
15 minutes at 4°C. The supernatants were precleared by gentle rotation with 5 μl protein 
G magnetic beads for 1 hour at 4°C. The supernatants were incubated with 2 μg antibodies 
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directed to MT1-MMP (Abcam, ab38971) or species specific IgG (Invitrogen) for 14 
hours at 4°C. 10 μl protein G magnetic beads were added to the lysates and gently rotated 
for 2 at 4°C. Beads were washed 6 times with 1 ml lysis buffer, without protease and 
phosphatase inhibitors. Proteins were eluted from the beads using 1.5x Laemmli sample 
buffer. Lysates were reduced with 2 % -mercaptoethanol and analyzed by western 
blotting, as described above.  
 
Human protein atlas 
Human cerebral cortex and glioma stained tissue sections are from The Human 
Protein Atlas available from www.proteinatlas.org (177). The tissue sections are stained 
for the alpha 1 chain of collagen type I (COL1A1), ITGA11, and MT1-MMP (MMP14). 
 
Statistical analyses 
All statistical analyses were performed using Prism 5 or Prism 6 (Graphpad 
Software, Inc.). Student’s t-test was performed on data comparing two samples. One-way 
ANOVA with Tukey’s Honest Significant Difference (HSD) post-hoc test was performed 
when comparing more than two samples. For ANOVA and Student’s t-test analyses, 
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RESULTS 
NIK increases expression of collagen binding integrin subunit alpha 11 
Studies in Chapter II show glioma cell invasion into 3D collagen matrices is 
variable and can be controlled by noncanonical NF-B signaling activation or inhibition 
(29, 30, 157). NF-B-inducing kinase (NIK or MAP3K14) is constitutively degraded 
under basal conditions, but when stimulated, NIK expression is stabilized leading to 
activation of noncanonical NF-B signaling through RelB nuclear translocation to act on 
target genes (17-19). In addition to regulation of invasion, Chapter II shows that 
expression of NIK controlled formation of pseudopodia and cell spreading on collagen in 
glioma cells (157). To investigate a mechanism by which NIK regulates these responses 
on collagen, we performed an initial screen of integrin subunits which form receptors for 
multiple ECM proteins to determine whether NIK could control pseudopodia formation 
and cell spreading through specific integrins. Initial experiments compared non-invasive 
BT114 glioma cells expressing a Vector Control to BT114 cells expressing a stabilized, 
constitutively active from of NIK (NIK(S867A)). We found that mRNA expression of the 
integrin 11 (ITGA11) subunit, which binds type I collagen, was upregulated in BT114-
NIK(S867A) cells compared to BT114 cells expressing a vector control (BT114-Control) 
(Figure 19). No significant changes were seen in expression of the ITGA1, ITGA2, 
ITGA3, ITGA6, ITGAV, ITGB1, or ITGB4 subunits, indicating a selective upregulation 
of the ITGA11 subunit.  
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Previously we have found, and show here, that glioma lines isolated from primary 
tumors display different invasive capabilities into collagen, which positively correlates 
with expression of the noncanonical NF-B transcription factor, RelB (29, 30, 157). Based 
on this observation, we next determined whether glioma cell invasion into collagen 
correlated with ITGA11 subunit expression. Wild-type glioma cells (BT114, BT25, and 
U87) were seeded onto 3D collagen matrices and allowed to invade overnight. Side view 
images of invasion and quantification of invasion density demonstrate that BT25 and U87 
cells were more invasive than BT114 cells (Figure 20A, B). To examine cell attachment 
to collagen, a phenotype controlled by integrin ligation to matrix proteins, we performed 


















Figure 19. Expression of NIKS867A in non-invasive BT114 cells increases ITGA11 mRNA 
expression.  
mRNA was isolated from BT114 cells expressing a Vector Control (Control) or NIK(S867A). qPCR 
analysis was performed using primers directed to ITGA1, ITGA2, ITGA3, ITGA6, ITGA11, ITGAV, 
ITGB1, ITGB4, and GAPDH. All ΔΔCT values were normalized to the GAPDH value for each respective 
sample and set relative to the Vector Control. ΔΔCT values were converted to 2-ΔΔCT to compare the 
relative mRNA fold change expression between BT114 -Control and -NIK(S867A) cells. 
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collagen, and allowed to attach for 30 minutes before washing away unattached cells and 
fixing, as described previously (178). While all cell lines were able to attach to 
immobilized collagen, the more invasive BT25 and U87 cells were significantly more 
adherent than BT114 cells (Figure 20C). Using quantitative real time PCR (qPCR), we 
examined mRNA expression of the four integrin subunits (ITGA1, ITGA2, ITGA10, and 
ITGA11) known to dimerize with the ITGB1 subunit to form collagen receptors.  
Compared to the other alpha chains, ITGA11 was the most highly upregulated in the more 
invasive glioma lines, BT25 and U87, compared to the non-invasive BT114 cells (Figure 
20D). These data demonstrate more invasive glioma cells display both increased 
adherence to collagen and expression of the collagen binding integrin subunit, ITGA11. 
 
Type I collagen, ITGA11, and MT1-MMP expression are upregulated in human glioma 
The ECM of the normal brain consists mostly of hyaluronan, tenascin-C, 
proteoglycans, and basement membrane proteins surrounding the vasculature (158). 
Normal brain expresses very little fibrillar matrix proteins, such as type I collagen, making 
it a soft tissue. Recently, Huijbers et al., showed positive Masson’s Trichrome staining for 
collagen fibers in glioblastoma multiforme (GBM) and further, the two alpha subunits 
which make up type I collagen are in the top one hundred genes upregulated in GBM 
compared to grade III gliomas (107). Staining performed by The Human Protein Atlas 
(177) demonstrates that type I collagen, ITGA11 and the membrane-bound protease which 
degrades collagen, MT1-MMP, are upregulated in high grade glioma, compared to normal 
brain tissue (Figure 21). These data demonstrate upregulation of collagen and the ITGA11 
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collagen receptor in glioma, reinforcing the relevance of studying ITGA11 in glioma 
invasion.  
 
NIK expression controls ITGA11 expression in high grade glioma 
To test whether NIK controlled the expression of ITGA11 beyond the initial screen 
of integrin subunits (Figure 19), we examined glioma cell adherence to collagen and the 

























Figure 20. Glioma cell invasiveness and adhesion to type I collagen is correlated with ITGA11 
expression.  
(A) BT114, BT25 and U87 glioma cells were seeded onto 2 mg/ml collagen matrix and allowed to 
invade 24 hours, fixed and stained with toluidine blue. Side view images of invasion shown, scale bar 
= 50μm. (B) Average invasion densities +/-SD from panel A. ***p<0.01 using Student’s t-test. (C) 
Average absorbance values +/-SD from BT114, BT25, and U87 cells stained with 0.1% amido black 
after adhesion assays on 1.25 ug/ml col I. **p<0.01 using Student’s t-test. (D) qPCR analysis using 
indicated primer pairs, showing fold change gene expression relative to BT114 cells. All values were 
normalized to RPLPO control. Representative experiment shown (n=2). 
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Our previous findings indicated that increased NIK expression enhanced BT114 cell 
invasion compared to BT114 cells expressing luciferase control (Chapter II, (157)). In 
adhesions assays, BT114-NIK(S867A) cells displayed increased adhesion to collagen 
compared to BT114-Control cells. However, cell adhesion to osteopontin (OPN), a ligand 
for integrins that recognize RGD and LDV sequences, was not affected by increased NIK 
expression (Figure 22A). We next examined mRNA expression of the integrin alpha 
subunits that form collagen receptors in BT114-Control cells, BT114 cells expressing a 
wild-type NIK construct (NIK(WT)), and BT114-NIK(S867A) cells. Compared to the 

























Figure 21. Col I A1, ITGA11, and MT1-MMP are upregulated in glioma.   
Collagen I, subunit A1 (Col I A1), ITGA11 and MT1-MMP staining of normal or glioma tissue in the 
cerebral cortex. Scale bars=100 µm. Staining performed by The Human Protein Atlas.  
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NIK(WT), or NIK(S867A), (4- and 42- fold greater, respectively) compared to Control 
cells (Figure 22B). Further, examination of ITGA11 protein expression by western 
blotting revealed a corresponding upregulation of ITGA11 in BT114 cells expressing 
NIK(WT) and NIK(S867A) compared to Control cells (Figure 22C).  
 
 
We next examined adherence to collagen and integrin expression in the invasive 
BT25 glioma cell line after NIK had been knocked out using CRISPR/Cas9/small guide 
RNA-mediated deletion of NIK (sgNIK). We have previously found that deletion of NIK 
in BT25 cells significantly attenuates BT25 cell invasion into 3D collagen (Chapter II, 
(157)). In adhesion assays, BT25-sgNIK cells were less adherent to collagen compared to 















Figure 22. NIK promotes glioma cell spreading, attachment, and pseudopodia formation.  
(A) BT114 cells expressing the vector (Control) or NIK(S867A) were seeded onto 1.25 µg/ml collagen 
type I (Col I) or osteopontin (OPN) and allowed to attach 30 minutes. Cells were rinsed and remaining 
cells were stained with 0.1% amido black. Graph shows average absorbance at 595 nm after adhesion 
assay. **p<0.01 using Student’s t-test. (B) mRNA was isolated from BT114 -Control, -NIK(WT), and 
-NIKS867A cells and used for qPCR analysis with primers directed to ITGA1, ITGA2, ITGA10 and 
ITGA11, showing fold change gene expression relative to BT114-Control. All values were normalized 
to RPLPO control. (C) Western blotting analysis of lysates made from BT114 -Control, -NIK(WT), 
and -NIKS867A cells using antibodies against ITGA11 and GAPDH. 
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(Figure 23A). Examination of ITGA1, ITGA2, ITGA10 and ITGA11 mRNA expression 
revealed that deletion of NIK in BT25 cells decreased expression of ITGA11 compared to 
BT25-Control cells (Figure 23B). Correspondingly, BT25-sgNIK cells also exhibited 
decreased ITGA11 expression at the protein level (Figure 23C). These data indicate that 
NIK controls the adhesion of glioma cells to collagen, possibly by regulating the 




















Figure 23. NIK silencing inhibits glioma cell spreading, attachment, and pseudopodia formation.  
(A) BT25 cells expressing the vector (Control) or sgNIK were seeded onto 1.25 µg/ml collagen type I 
(Col I) or osteopontin (OPN) and allowed to attach 30 minutes. Cells were rinsed and remaining cells 
were stained with 0.1% amido black. Graph shows average absorbance at 595 nm after adhesion assay. 
*p<0.05 using Student’s t-test. (B) mRNA was isolated from BT25 -Control and –sgNIK cells and used 
for qPCR analysis with primers directed to ITGA1, ITGA2, ITGA10 and ITGA11, showing fold change 
gene expression relative to BT25-Control cells. All values were normalized to RPLPO control. (C) 
Western blotting analysis of lysates made from BT25 -Control and -sgNIK cells using antibodies 
against ITGA11 and Actin. 
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ITGA11 silencing attenuates glioma cell invasion 
To evaluate a role for ITGA11 in glioma cell invasion, we used lentiviral-mediated 
delivery of short hairpin RNAs to knockdown ITGA11 (shITGA11) or GAPDH 
(shGAPDH) expression, as a control. We used the U87 glioma cell line to knockdown 
expression of ITGA11 as we have found these cells to be highly invasive (29, 30, 157) 
and express high levels of ITGA11 (Figure 20). We first confirmed knockdown of 
GAPDH and ITGA11 in the U87-shGAPDH and U87-shITGA11 cells, respectively. 
Additionally, ITGA11 shares strong sequence similarity with ITGA1 and ITGA2; 
therefore, we confirmed that the ITGA11 short hairpin did not have significant unintended 
off target effects on mRNA expression of ITGA1 and ITGA2 (Figure 24A). In invasion 
assays, we observed that knockdown of ITGA11 significantly diminished U87 invasion 
into 3D collagen matrices, compared to shGAPDH control cells (Figure 24B). Side view 
images of invasion demonstrate dramatic attenuation of both invasion density and distance 
into the collagen matrix in U87-shITGA11 cells (Figure 24C). Together, these results 
support that NIK controls the expression of ITGA11, which plays a significant role in the 
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ITGA11 complexes with MT1-MMP 
We have previously found that NIK regulates MT1-MMP phosphorylation (Y573) 
and localization to cortactin-rich pseudopodial structures (Chapter II, (157)). MT1-MMP 
degrades collagen, along with other basement membrane and ECM proteins to facilitate 
cell invasion. Phosphorylation of MT1-MMP at Y573 directs the protease to the plasma 
membrane, where it is tethered and can interact with other transmembrane proteins, the 



























Figure 24. Silencing of ITGA11 decreases U87 invasion.  
U87 cells were transduced with shRNA directed to GAPDH or ITGA11, seeded onto 2 mg/ml collagen 
type I matrices, and allowed to invade 48 hours. (A) mRNA was isolated from U87 –shGAPDH and -
shITGA11 cells and used for qPCR analysis comparing integrin, GAPDH, and B-actin mRNA 
expression. (B) Quantification of average invasion density +/- SD ***p<0.001 using Student’s t-test. 
Data shown are average values +/- s.d. (C) Side view images of invasion shown, scale bar = 100μm. 
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and enriched at sites of integrin-matrix adhesion to initiate directed collagen degradation 
and invasion (79, 81, 82, 113, 114, 168, 179). We therefore investigated whether MT1-
MMP could form a complex with ITGA11. Using a heterologous system, MT1-MMP was 
co-expressed in HEK293FT cells with either GFP or ITGA11-Flag. Immunoprecipitation 
experiments determined ITGA11 complexed with MT1-MMP when co-expressed in 
HEK293FT cells (Figure 25). These data suggest that ITGA11 complex formation with 
MT1-MMP in glioma cells could enable coordinated, localized matrix degradation at sites 
























Figure 25. ITGA11 complexes with MT1-MMP in HEK293FT cells.  
HEK293FT cells were transiently transfected to express MT1-MMP and either Flag-tagged ITGA11 
or GFP control. MT1-MMP or isotype control were immunoprecipitated from cleared lysates and 
eluates were probed for MT1-MMP, ITGA11, and GAPDH during western blotting. 
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NIK promotes a leader cell phenotype in glioma 
In breast cancer, ITGA11 has recently been identified as a marker of leader cells 
which facilitate collective cell migration (44). As we found NIK could regulate the 
expression of ITGA11 in glioma cells, we wondered whether NIK might drive a leader 
cell phenotype in 3D collagen matrices. We tested this through invasion assays using the 
invasive BT25-Control cells, which have relatively high NIK expression (157) and the 
BT25-sgNIK cells where NIK has been deleted (Figure 26A). As before, BT25-Control 
cells showed significant invasion into collagen matrices, while the BT25-sgNIK cells were 
less invasive (Figure 26B). However, when both cell types were combined, the number of 
invading BT25-sgNIK cells increased significantly (Figure 26A, B). Quantification of 
invasion distance past the original monolayer demonstrated BT25-Control cells invaded 
significantly further than the BT25-sgNIK cells, when seeded separately. When the two 
cell types were seeded in equal ratios, the BT25-sgNIK gained the ability to invade 
comparably to the BT25-Control cells (Figure 26C). This suggests a leader and follower 
cell relationship between cells with high NIK expression and cells lacking NIK, 
respectively, where NIK promotes a leader cell phenotype, stimulating the invasion of 
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ITGA11 expression correlates with invasiveness in other collagen-rich tumors 
 Since the expression of ITGA11 positively correlates with glioma cell 
invasiveness and promotes glioma cell invasion through 3D collagen matrices, we were 
interested in investigating if ITGA11 expression correlated with invasiveness of other 
tumor types. We chose to examine osteosarcoma and melanoma tumors, which typically 
must invade through dense type I collagen matrices. During invasion assays, MG63 human 























Figure 26. NIK expressing cells promote invasion of BT25 cells lacking NIK.  
(A) BT25 cells expressing a vector control (BT25-Control) were labeled with DiO (green) and BT25-
sgNIK were labeled with DiI (red). Cells were seeded separately or together into 2 mg/ml collagen type 
I matrices and allowed to invade 48 hours. Nuclei were labeled with DAPI (blue). Side view of invasion 
shown. Scale bar = 10μm. (B) Graph shows quantification of invasion density. After removing fixed 
collagen gels from the wells, gels were cut, mounted, and imaged from the side using confocal 
microscopy. The average number of invading cells per 100 µm +/- SD is shown. Different letters 
represent statistically significant differences calculated with an ANOVA and Tukey’s HSD. (C) 
Quantification of invasion distance. Data shown are average values +/- SEM. Different letters represent 
statistically significant differences calculated with an ANOVA and Tukey’s HSD. 
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correspondingly, also had increased expression of ITGA11 mRNA (Figure 27C). M4, M7 
and M9 human melanoma cells were less invasive than the M6, M8, M10, WM115, and 
WM266 cells (Figure 28A and B) and also expressed relatively less ITGA11 mRNA 
during qPCR analyses (Figure 28C). Taken together, these data suggest that ITGA11 could 
be used as a general marker for more invasive human tumors. Together, our data in glioma 
support a correlation between NIK or noncanonical NF-B signaling and ITGA11 

























Figure 27. ITGA11 expression correlates with invasiveness of human osteosarcoma cells.  
UWOS2 and MG63 osteosarcoma cells were seeded onto 2 mg/ml collagen type I matrices, and allowed 
to invade 48 hours. (A) Side view images of invasion shown, scale bar = 50μm. (B) Quantification of 
average invasion density +/- SD ***p<0.001 using Student’s t-test. (C) mRNA was isolated from UWOS2 
and MG63 cells and used for qPCR analysis comparing ITGA11, showing fold change gene expression 
relative to UWOS2 cells. All values were normalized to GAPDH control.  
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DISCUSSION 
Although it has become increasingly apparent that noncanonical NF-B signaling, 
through increased NIK activity, mediates the development and progression of a number 
of cancers (24-28), the mechanism by which NIK regulates tumor cell invasion is not well 
known. In the context of glioma, our previous studies have found NIK promotes glioma 





























Figure 28. ITGA11 expression correlates with invasiveness of human melanoma cells.  
M4, M6, M7, M8, M9, M10, WM115, and WM266 melanoma cells were seeded onto 2 mg/ml collagen 
type I matrices, and allowed to invade 48 hours. (A) Side view images of invasion shown, scale bar = 
50μm. (B) Quantification of average invasion density +/- SD. (C) mRNA was isolated from indicated 
melanoma cells and used for qPCR analysis comparing ITGA11, showing fold change gene expression 
relative to M4 melanoma cells. All values were normalized to GAPDH control.  
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structures (157). Here we provide evidence that in glioma cells, NIK increases the 
expression of ITGA11, and promotes a leader cell phenotype in collagen. Consistent with 
studies of breast cancer (44), ITGA11 was required for glioma cell invasion, and ITGA11 
expression correlated with increased invasiveness in glioma, melanoma, and osteosarcoma 
cells. 
 In agreement with findings of collagen deposition within the glioma tumor stroma 
(107), staining from The Human Protein Atlas demonstrates increased expression of type 
I collagen in glioma tumor sections. While the normal brain is a soft tissue, the deposition 
of collagen within the tumor increases the stiffness of the tumor stroma. Using ultrasound, 
several studies have found glioma tissue is stiffer than the surrounding environment (180, 
181). Increased collagen stiffness has been found to activate canonical NF-B signaling 
(182), though whether noncanonical NF-B signaling is activated by the same mechanism 
is unknown.  
Recent studies have found the aggressiveness of glioma and poor patient prognosis 
are correlated with increased stiffness of the glioma ECM (183). Correspondingly, 
collagen deposition correlates with increasing glioma tumor grade (107). Furthermore, 
glioma cell invasion often follows stiffer areas of the brain, such as white matter and along 
the basement membrane of blood vessels (184, 185). Increased collagen stiffness has been 
found to enhance glioma cell motility, invasiveness, and proliferation (186-188). These 
studies of collagen in glioma relate to investigations in breast cancer, where tissue stiffness 
is known to promote the conversion of normal breast epithelial cells to tumor cells (189, 
190). Increased breast density, caused by collagen deposition, is one of the greatest 
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independent risk factors for development of breast cancer, conferring a 4-6 increased risk 
in patients (191-194). Stromal collagen deposition increases matrix stiffness causing 
activation of signaling pathways which promote tumor cell invasion, survival, and growth 
(195). Our finding that ITGA11 expression correlates with more invasive glioma cells 
provides an explanation for how glioma cells could recognize and respond to the increased 
collagen deposition to promote a more invasive phenotype. 
 Our study is the first to show NIK can promote collective invasion, enhancing the 
invasiveness of glioma cells not capable of invading into collagen. NIK controls the 
expression of ITGA11, a marker of leader cells which initiate collective invasion in breast 
cancer (44). Knockdown of ITGA11 in glioma cells abrogated invasion, suggesting NIK-
dependent ITGA11 expression may be a critical component of collective invasion, in 
glioma as well. ITGA11 expression correlated with melanoma and osteosarcoma cell 
invasiveness, although whether NIK regulates ITGA11 expression to promote 
invasiveness in these tumors remains to be determined. Interestingly, NIK has been found 
to be upregulated in melanoma and is thought to contribute to pathogenesis through 
inhibition of cellular senescence (196, 197). Similar to breast cancer, melanoma cells have 
been shown to utilize the collective mode of cell invasion (101). Therefore, it will be 
important to investigate whether NIK-mediated collective invasion seen in glioma could 
be more universal mechanism controlling tumor cell invasion. Whether the follower cells 
are invading through tunnels created in the matrix (138) by the leader cells, or the follower 
cells recognize proinvasive factors produced by the leader cells, remains to be determined. 
Regardless, the ability of NIK to promote collective invasion in glioma underscores the 
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importance of targeting noncanonical NF-B signaling, as this invasion mechanism could 
be a fundamental factor underlying glioma recurrence.   
 Critical to cell migration following integrin adhesion to matrix substrates is 
remodeling of the ECM by matrix proteases. In particular, integrins and the collagenase 
MT1-MMP are thought to cooperate to facilitate coordinated matrix proteolysis and cell 
invasion. MT1-MMP is capable of degrading a wide range of ECM and basement 
membrane proteins, such as collagen type I, II, and III, fibrin, fibronectin, vitronectin, and 
laminin (61, 68-70). Further, MT1-MMP has also been shown to complex with several 
integrin receptors, including v3, 31, and 21, which form receptors for these matrix 
proteins (75, 81, 83). Here we provide evidence that MT1-MMP can form a complex with 
ITGA11, adding to a growing list of interactions which can facilitate and precisely direct 
coordinated cell adhesion, matrix proteolysis, and migration. Altogether, these studies 
provide a mechanism through which noncanonical NF-B signaling promotes glioma cell 
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
CONCLUSIONS 
 The results in Chapter II demonstrate that NIK, a critical upstream regulator of 
noncanonical NF-B signaling mediates glioma cell invasion into 3D type I collagen 
matrices. NIK expression also positively correlated with glioma cell invasiveness. As a 
possible mechanism through which NIK drives glioma cell invasion, we found NIK 
regulated the activity and phosphorylation of the collagen protease, MT1-MMP, though 
likely through indirect means. The formation of invasive pseudopodial protrusions and 
cell shape on collagen matrices were also controlled by NIK expression. NIK enhanced 
localization of activated MT1-MMP to pseudopodial structures in both glioma cells and 
MEFs. Importantly, NIK controlled these critical components of cell invasion 
independently of the canonical NF-B pathway.  
 Staining of human patient glioma tumor sections demonstrated both NIK and 
phosphorylated MT1-MMP were co-expressed in glioma cells. Further, staining of glioma 
tumor xenografts revealed expression of phosphorylated MT1-MMP correlated with 
increased NIK expression. Finally, through examination of clinical databases, we found 
co-expression of NIK and MT1-MMP in human patient tumors was associated with poorer 
patient survival rates. These results help to explain how noncanonical NF-B signaling, 
through NIK, promotes the invasiveness of glioma cells and suggest inhibiting this 
pathway therapeutically may have benefit for glioma patients.  
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 Chapter III reveals a potential mechanism through which NIK could control 
glioma cell shape changes and recruitment and activation of MT1-MMP at pseudopodia, 
as well as promote invasion into collagen matrices. Initially, we determined that 
expression of the collagen-binding ITGA11subunit was correlated with more invasive 
glioma cell lines. Staining performed by The Human Protein Atlas demonstrated ITGA11, 
type I collagen, and MT1-MMP expression were upregulated in glioma tissue, compared 
to normal brain tissue. Modulation of NIK expression revealed NIK upregulation 
increased both the mRNA and protein expression of ITGA11, while NIK silencing 
conversely decreased ITGA11 expression. Knockdown of ITGA11 in an invasive glioma 
cell line also attenuated invasion into 3D type I collagen matrices, indicating ITGA11 
could be a key mediator of NIK-driven glioma cell invasion. 
 Interestingly, ITGA11 has been found to be a functional marker of leader cells in 
breast cancer, which promote collective cell invasion (44). As NIK controlled the 
expression of ITGA11 in glioma cells, we investigated whether NIK could initiate 
collective cell invasion of glioma cells. In co-culture invasion assays, NIK-expressing 
cells increased the invasion distance and density of non-invasive cells, demonstrating NIK 
enhances the formation of a leader cell phenotype in invasive cells and mediates the 
invasion of normally non-invasive cells.  
Collectively, these studies provide further evidence that noncanonical NF-B 
signaling promotes the invasiveness of glioma cells. NIK increases the expression of the 
integrin ITGA11 subunit, which forms a type I collagen binding integrin. ITGA11 can 
promote the adhesion of glioma cells to collagen matrices. Integrin adhesion to matrix 
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substrates is well known to initiate formation of pseudopodial structures (77, 78), which 
we have shown are driven by NIK expression. NIK also promotes the phosphorylation, 
activity, and recruitment of the collagenase MT1-MMP to invasive pseudopodial 
structures. Altogether these phenotypes provide a mechanism by which NIK can drive 


































Figure 29. Mechanism of NIK-driven glioma cell invasion. 
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FUTURE DIRECTIONS 
 In these studies, we have found noncanonical NF-B signaling, through 
stabilization of NIK, drives glioma cell invasion into 3D collagen matrices. NIK also 
regulates the mRNA and protein expression of ITGA11. Knockdown of ITGA11 
decreases glioma cell adhesion to collagen in 2D and invasion into 3D collagen matrices. 
These results lend themselves to further investigation. 
 While mRNA expression of ITGA11 was controlled by NIK, whether ITGA11 is 
a transcriptional target of RelB, or if ITGA11 transcription is regulated by noncanonical 
NF-B signaling by indirect means remains to be determined. Another important question 
is if ITGA11 activity is both necessary and sufficient for noncanonical NF-B-driven 
glioma invasion. NIK is known to control several mechanisms which promote an invasive 
phenotype (29, 198); consequently, it is unlikely that ITGA11 would be sufficient to 
completely rescue invasion with the loss of NIK. However, even a partial rescue would 
highlight the importance of ITGA11 for glioma cell invasion. Knockdown of ITGA11 
almost completely abolished U87 cell invasion; therefore, ITGA11 is expected to be 
necessary for NIK-induced glioma cell invasion.  
 In the setting of lung cancer, ITGA11 expression correlates with increasing tumor 
grade and poor prognosis in patients (41). While we have found ITGA11 expression is 
upregulated in glioma tissue compared to normal brain tissue, and its expression is 
increased in more invasive glioma cells, whether ITGA11 expression is correlated with 
higher grade tumors and poor patient outcomes is unknown. Additionally, ITGA11 
expression reduces glioma cell adhesion to collagen and invasion into 3D collagen 
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matrices. Cells must adhere to their surroundings to degrade and migrate through the 
extracellular millieu. Integrins have been shown to be essential for these functions, as well 
as for promoting cell growth and survival; therefore, it would be intruging to determine 
how the attenuation of these behaviors in vitro would translate in vivo during orthotopic 
tumor xenograft experiments.  
Further, as tumors are made up of a hetergeneous population of cells, an interesting 
question is where ITGA11 and NIK are expressed within the tumor mass. As NIK 
promotes an invasive phenotype, increased expression in the cells at the tumor border may 
occur. This would promote invasiveness at the tumor periphery, where cells are exposed 
to collagen, and moreover, as NIK enhances expression of ITGA11, this would further 
drive an invasive phenotype. These proteins have the potential to serve as markers of more 
invasive cells which could contribute to glioblastoma recurrence. Another possibility is 
the contribution of ITGA11 binding to collagen leading to a feed-forward loop through 
activation of NIK. Integrin signaling is known to enhance receptor tyrosine kinase 
activation, enhancing downstream signaling. Whether ITGA11 ligation to collagen 
promotes stabilization of NIK and downstream NF-B signaling is unknown. 
 Another important area for potential investigation is targeting ITGA11 
therapeutically. We have shown ITGA11 is not highly expressed in the normal brain, 
which corresponds to a lack of type I collagen deposition under normal conditions. 
Therefore, inhibiting ITGA11 could serve as an attractive therapy in the brain with the 
potential of specifically targeting only tumor cells. ITGA11 is a transmembrane protein, 
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with domains exposed on either side of the cell membrane, perhaps leading it to be a more 
“druggable” target. 
During glioma cell invasion assays, we found NIK promoted collective invasion, 
allowing normally non-invasive cells to migrate into the collagen matrix behind leader 
cells. Several questions remain to be answered with regard to how NIK and ITGA11 drive 
this type of invasion. The cells expressing NIK could solely act to degrade the matrix in 
an MMP-dependent manner, forming a tunnel for non-invasive cells to migrate through, 
in a MMP-independent manner. Alternatively, NIK and ITGA11 expressing cells could 
release pro-invasive factors, which promote the normally non-invasive cells to follow.  
ITGA11 expression has been shown to increase with increasing tumor grade in 
lung cancer (41) and control the invasiveness of leader cells in breast cancer (44). The 
data here show that ITGA11 expression also positively correlates with invasiveness in 
osteosarcoma and melanoma. While increased NIK expression has been linked to lung and 
melanoma cancer (26, 196, 197), whether noncanonical NF-B signaling is elevated in 
the setting of these cancers to control ITGA11 expression and invasion is unknown. If so, 
it could point a more universal mechanism of tumor cell invasion, further underscoring 
the need to develop therapeutics against noncanonical NF-B signaling and its targets.  
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